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Inhaled nanoparticles are a promising technology for delivering therapeutic 
molecules to the lungs to treat diseases such as cystic fibrosis (CF) and lung cancer. This 
dissertation focuses on characterizing and overcoming a critical extracellular barrier to 
inhaled nanomedicine: the mucus gel that coats the lung airway epithelium. Mucus is an 
adhesive meshwork that can trap particles and facilitate their removal from the lungs via 
mucociliary clearance. Although this defense mechanism protects the lungs from 
pathogens and particulate pollution, it can also prevent inhaled drug and gene 
nanoparticles from reaching their target. We therefore investigated strategies to improve 
particle penetration through human lung mucus. To measure nanoparticle transport, we 
used multiple particle tracking, a high resolution microscopy technique for quantifying 
movement of individual particles. 
First, we examined how particle size and surface chemistry affect mobility in 
respiratory mucus. We prepared polymeric nanoparticles densely coated with low 
molecular weight polyethylene glycol (PEG) to minimize muco-adhesion, and compared 
their transport to that of uncoated, muco-adhesive particles in respiratory mucus collected 
from endotracheal tubes of surgical patients without pulmonary comorbidities. We found 
that 100 and 200 nm diameter PEG-coated particles rapidly penetrated respiratory mucus, 
at rates exceeding their uncoated counterparts by more than one order of magnitude. In 
contrast, coated and uncoated particles 500 nm in diameter were sterically immobilized 
by the mucus mesh. These findings identify small size and adhesion-resistant surface as 
design criteria for therapeutic, respiratory-mucus-penetrating nanoparticles. 
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Next, we studied viruses – nature’s nanoparticles – for CF lung gene therapy. We 
investigated whether CF sputum acts as a barrier to adeno-associated virus (AAV) gene 
vectors including AAV2, the serotype tested in CF clinical trials, and AAV1, a leading 
candidate for future trials. We found that sputum strongly impeded diffusion of AAV, 
regardless of serotype, and may thereby inhibit access to target cells. However, an AAV2 
mutant engineered to have reduced heparin binding diffused twice as fast as AAV2 on 
average, presumably because of reduced adhesion to sputum. We also discovered that the 
mucolytic N-acetylcysteine could markedly enhance AAV diffusion. These studies offer 
strategies for increasing AAV penetration through sputum to improve clinical outcomes. 
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1.1. Overview and significance 
Inhaled nanoparticles are a promising approach for delivering therapeutic 
molecules to the lungs with increased efficacy and decreased side effects. Examples of 
inhaled nanomedicines currently under investigation include gene vectors for cystic 
fibrosis (CF), chemotherapeutic-loaded particles for lung cancer, and antibiotic 
nanoparticles for lung infections.1 However, extracellular barriers can trap inhaled 
nanoparticles and prevent the therapeutic cargo from reaching its intended site of action. 
This dissertation is about characterizing extracellular barriers to inhaled nanomedicines, 
and overcoming these barriers for therapeutic applications. Specifically, we focus on the 
viscoelastic mucus gel that coats the lung airways. Mucus can trap particles and facilitate 
their removal from the lungs by mucociliary clearance, rendering the therapeutic 
nanoparticles less effective. 
A key experimental method we used in these investigations was particle tracking, 
an optical microscopy technique for recording the motion of individual particles in 
complex environments at high spatial and temporal resolution. We implemented a user-
friendly automated tracking code in MATLAB, based on the established algorithm of 
Crocker and Grier,2 which enabled us to process hundreds of particle tracking videos and 
analyze tens of thousands of particle trajectories. Following this introductory chapter, we 
discuss particle tracking methods for drug and gene delivery in Chapter 2 (and we 
provide the tracking code in the Appendix). The transport rate measured by particle 
tracking indicates the ability of a specific nanoparticle type to penetrate a given 
biological specimen and reach the desired therapeutic target. 
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A major role of respiratory mucus is to trap inhaled particles, including pathogens 
and environmental particulates, to limit body exposure. Despite the tremendous health 
implications, how particle size and surface chemistry affect mobility in respiratory mucus 
from humans without lung disease was not known until our work in Chapter 3. We 
prepared polymeric nanoparticles densely coated with low molecular weight polyethylene 
glycol (PEG) to minimize muco-adhesion, and compared their transport to that of 
uncoated, muco-adhesive particles in human respiratory mucus, which we collected from 
the endotracheal tubes of surgical patients with no respiratory comorbidities. We found 
that PEG-coated particles 100 and 200 nm in diameter rapidly penetrated respiratory 
mucus, at rates exceeding their uncoated counterparts by approximately 15- and 35-fold, 
respectively. In contrast, PEG-coated particles ≥ 500 nm in diameter were immobilized 
by the mucus mesh. Thus, even though respiratory mucus is a viscoelastic solid at the 
macroscopic level (as measured using a bulk rheometer), nanoparticles that are 
sufficiently small and non-adhesive can penetrate the mucus as if it were primarily a 
viscous liquid. These findings help elucidate the barrier properties of respiratory mucus 
and provide design criteria for therapeutic nanoparticles capable of penetrating mucus to 
approach the underlying airway epithelium.  
Next, we studied lung gene therapy for CF, which we describe in Chapter 4. CF is 
caused by a genetic defect in the CFTR chloride channel, and while this defect affects a 
number of organs, lung disease is the greatest cause of morbidity and mortality in CF 
patients. Despite promising preclinical studies, gene therapy has not yet improved CF 
patient lung function in human trials. In the human CF lung, inhaled gene vectors must 
penetrate the viscoelastic secretions coating the airways to reach target cells in the 
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underlying epithelium. We investigated whether CF sputum acts as a barrier to leading 
adeno-associated virus (AAV) gene vectors, including AAV2, the only serotype tested in 
CF clinical trials, and AAV1, a leading candidate for future trials. We found that sputum 
strongly impeded diffusion of AAV, regardless of serotype, by adhesive interactions and 
steric obstruction. Approximately 50% of AAV vectors diffused >1,000-fold slower in 
sputum than in water, with large patient-to-patient variation. We thus tested two 
strategies to improve AAV diffusion in sputum. We showed that an AAV2 mutant 
engineered to have reduced heparin binding diffused twice as fast as AAV2 on average, 
presumably because of reduced adhesion to sputum. We also discovered that the 
mucolytic N-acetylcysteine could markedly enhance AAV diffusion by altering the 
sputum barrier properties. These studies underscore that sputum is a major barrier to CF 
gene delivery, and offer strategies for increasing AAV penetration through sputum to 
improve clinical outcomes. 
Thus, in this dissertation we probed and tested strategies to overcome 
extracellular barriers to inhaled nanomedicines. We conclude with a future outlook on the 
field in Chapter 5.   
 
1.2. Background 
1.2.1. Cystic fibrosis and CF gene therapy 
Cystic fibrosis is an autosomal recessive disorder that afflicts approximately 
70,000 people worldwide.3 CF is caused by a mutation in the CF transmembrane 
conductance regulator gene (CFTR) on chromosome 7.4 The CFTR gene codes for an ion 
channel that conducts chloride across cell membranes. Approximately 4% of Caucasians 
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carry one CF mutation.5 Nearly 2,000 variants of the gene have been identified, of which 
127 are known to be deleterious.3 About 70% of defective CFTR alleles have the most 
common mutation, called F508del, which causes defective maturation and premature 
degradation of the CFTR protein.4 
 Cystic fibrosis affects the mucus-covered lumens of the body, including the 
lungs, pancreatic ducts, reproductive tract, and GI tract. Lung disease is the main source 
of morbidity and mortality in CF. A vicious cycle of impaired mucociliary clearance, 
infection, and inflammation takes a toll over time, causing bronchiectasis and declining 
lung function. Approximately 90% of patients with CF also suffer from pancreatic 
enzyme insufficiency, and nearly all males with CF are infertile.5,6 The median life span 
of CF patients has increased in recent decades, thanks to aggressive treatment. The three 
pillars of CF treatment are antibiotic therapy for lung infections, respiratory therapy to 
clear lung obstruction, and enzyme replacement and dietary supplementation to achieve 
nutritional repletion.7 However, the median survival age of CF patients is still only 
approximately 40 years.6  
The CF gene was discovered in 1989, opening the possibility of treating CF by 
delivering the correct gene to cells to mediate proper CFTR activity. Numerous clinical 
trials for CF gene therapy have been conducted during the past two decades, using both 
viral and non-viral vectors, including adenovirus, adeno-associated virus, and liposomes. 
However, the results have been disappointing. There are a variety of possible reasons for 
these poor results, including immune response to the vectors and poor cellular targeting.8 
In this dissertation, we investigated an important but often overlooked barrier to CF gene 
therapy: the sputum barrier that obstructs CF patients’ lungs. 
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The gene therapy vector we studied here is adeno-associated virus (AAV), a 
leading viral vector currently under preclinical and clinical investigation for treating 
diseases of the lung, heart, liver, eye, and central nervous system.9 Between 1999 and 
2007, six clinical trials for CF were conducted using AAV serotype 2.8 AAV is promising 
for gene therapy because it does not cause any known disease, induces only mild immune 
response, and can efficiently transduce many cell types. AAV is a non-enveloped virus 
with an icosahedral capsid. With a diameter of approximately 25 nm, it is among the 
smallest of viruses. Dozens of AAV serotypes have now been discovered, with different 
receptors and tissue tropisms. In the recombinant AAV vectors used for gene therapy, the 
wild-type genes are removed and replaced with the therapeutic genes of interest. 
 
1.2.2. Drug and gene delivery to the lungs 
Delivery of therapeutics via inhalation offers a number of advantages for 
treatment of lung diseases ranging from asthma to CF. Compared to systemic delivery, 
inhalation permits local delivery with reduced side effects, and may require lower doses 
to achieve the desired therapeutic outcome.10 Inhaled therapeutics also avoid first-pass 
metabolism, which is an advantage relative to oral delivery.1 Although the focus of this 
dissertation is delivery to the conducting airways, we note that delivery to the alveoli is 
useful for targeting alveolar macrophages or for rapid systemic delivery, since the alveoli 
have a large surface area and a rich blood supply.1,11  
A number of devices are used to deliver medications to the lung. Metered-dose 
inhalers deliver a short burst of the therapeutic aerosol in a propellant. Dry powder 
inhalers deliver micron-sized drug particles, and no propellant is used. Nebulizers turn 
6 
 
liquid solutions or suspensions into a fine mist, which is inhaled.10 Particle deposition in 
the lungs is size-dependent. Large particles, with an aerodynamic diameter >5 µm, 
deposit by inertial impaction in the upper airways. Smaller particles, with 1-5 µm 
aerodynamic diameter, deposit deeper in the lungs by inertial impaction and 
sedimentation. The ideal size for deposition in the alveoli is 1-3 µm. A large fraction of 
particles under 1 µm remain suspended and are exhaled, though particles <100 nm may 
deposit in the alveoli by diffusion.1  
Increasingly, nanoparticle drug carriers are being explored in many areas of 
medicine for their ability to provide controlled release of therapeutics and achieve 
improved pharmacokinetics.1,11,12 Furthermore, for gene delivery, a virus or nano-sized 
vector is essential to protect the DNA cargo from enzymatic degradation and to facilitate 
cell entry and trafficking. For targeting the airways, drug nanoparticles and gene vectors 
are most often delivered by nebulization of the nanoparticle suspension. Nebulization 
permits control of droplet size and thus the location of deposition.1,10  
 
1.2.3. Mucus, mucociliary clearance, and mucus-nanoparticle interactions 
 Mucus is a viscoelastic gel that lubricates and protects wet epithelial surfaces in 
the body, including the conducting airways of the lungs. Mucus is more than 90% water. 
The solid components of mucus include mucins, globular proteins, lipids, salts, and cell 
debris. Mucins are large glycoproteins, up to 3 megadaltons in molecular weight, which 
give mucus its viscoelastic properties. Mucins are highly glycosylated, with sugars 
comprising 50-90% of the dry weight. These sugars are O-linked, attaching to long, 
flexible mucin regions rich in proline, threonine, and serine (PTS domains). At the ends 
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of most of the glycans are carboxyl or sulfate groups, which make mucins highly anionic. 
Mucins are stored in a dehydrated form, and upon secretion, the highly hydrophilic, 
negatively charged glycan-coated PTS domains swell with water.13 The glycan-rich 
domains on mucins are interspersed with relatively short, glycan-poor, hydrophobic 
domains.14 In the lung airways, the two main types of mucins are MUC5AC and 
MUC5B.13 Both are rich in cysteine residues at their termini, which permits disulfide 
bonding between mucins. Mucins can also crosslink via Ca2+ and physically entangle. 
Together, these mechanisms are responsible for mucus viscoelasticity.14  
 In the lungs, mucus is continuously produced, secreted, and then removed by 
mucociliary clearance. The airway epithelium is comprised of ciliated cells and mucus-
producing secretory cells; in the large airways (diameter > 2 mm), mucus is also 
produced in submucosal glands.13 The mucus gel layer sits atop the periciliary layer, 
which is composed of membrane-bound mucins and other cell-grafted macromolecules.15 
Mucociliary clearance (MCC) and cough remove inhaled particles, pathogens, and even 
dissolved chemicals that could harm the lungs. MCC velocity is approximately 1 
mm/min, but is highly dependent on the extent of mucus hydration and other variables.13  
In disease states, mucus hydration and composition can change. CF, for instance, 
is characterized by a lack of luminal liquid. Furthermore, neutrophils are abundant in the 
inflamed CF lung, and dead neutrophils leave behind DNA and actin that can alter mucus 
rheology. It is also believed that decreased bicarbonate secretion, a consequence of the 
CFTR mutation, contributes to excess mucin crosslinking by Ca2+.13 Bacteria in infected 
CF lungs can secrete and envelop themselves in biofilms, which can also alter the 
8 
 
rheology of CF airway secretions. The altered rheology contributes to poor MCC, which 
in turn promotes further lung infection, inflammation, and injury.  
Nanoparticles can interact in a number of ways with a porous biological gel such 
as mucus. If the particle is not adhesive and is small relative to the mesh size of the gel, it 
will be able to diffuse through the pores of the gel. If the particle is small but adhesive, it 
may adhere to the gel fibers and be immobilized. If the particle is large relative to the 
mesh size of the gel, it will be caged and cannot readily diffuse through the gel.16 This 








Successful nanoparticle-based drug and gene delivery depends on the transport 
behavior of the particles following their administration. To achieve therapeutic efficacy, 
drug and gene carriers must often diffuse through extracellular barriers,17-19 and gene 
carriers must be transported to the cell nucleus.20,21 Particle tracking is a powerful 
technique for studying transport processes by tracking the motion of individual particles 
at high spatial and temporal resolution using light microscopy. Particle tracking can 
quantify transport rates of drug carriers, imaging agents, synthetic gene vectors, and 
viruses in cells, tissues, and biological fluids.22 Compared to earlier techniques, which 
measure average values over entire ensembles of particles, tracking with single-particle 
resolution permits the analysis of heterogeneous particle behavior. 
Particle tracking has matured over the past three decades into a broadly accessible 
technique, useful in a variety of fields. Early applications were in cellular biophysics23,24 
and fundamental colloid science.2 During the past 15 years, our lab and others have 
harnessed particle tracking for drug and gene delivery research. Particle tracking 
experiments can be conducted with microscopes and modern cameras that are now 
standard in biomedical research facilities. Numerous software packages for analysis of 
particle tracking videos are now freely available, and they can perform well even when 
studying complex biological specimens. Users do not require much, if any, prior 
programming experience to process even large data sets. 
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To facilitate even more widespread adoption of this powerful technique in the 
field of drug and gene delivery, we present a user-friendly introduction to particle 
tracking methods, review the state of the art in tracking algorithms, and discuss how to 
minimize errors to achieve reliable results. 
 
2.2. Design of particle tracking experiments 
Time-lapse videos of particles in a specimen are the raw data in particle tracking 
experiments. Collecting videos with the highest possible quality – in short, bright 
particles with high contrast against a uniform background – will greatly simplify data 
analysis and enable reliable interpretation. Three critical factors that influence video 
quality are the particles, microscope, and camera. Here, we provide guidelines for their 
selection and use. Optical properties of the biological specimen under investigation will 
also strongly impact the quality of videos that can be acquired, but those factors are 
typically beyond a researcher’s control. 
A variety of particles and illumination schemes can be used for particle tracking, 
including micron-sized colloids imaged via brightfield illumination,2 and gold 
nanoparticles via darkfield microscopy.25 However, we focus our discussion on 
fluorescent particles and fluorescence microscopy, which are particularly useful for 
identifying drug and gene delivery nanoparticles in heterogeneous biological materials. 
The more intensely fluorescent the particle, the more reliable the particle identification 
and localization. Bright, fluorescent polystyrene nanospheres are commercially available 
from companies such as Life Technologies, Bangs Laboratories, and Polysciences, and 
they are often used as model drug and gene nanoparticles in particle tracking 
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studies.17,18,26 For researchers interested in tracking nanoparticles prepared in their own 
laboratories, a number of fluorescent labeling strategies are possible. Particles can be 
internally labeled, either by physically encapsulating the fluorescent dye in the particle 
core (though this strategy is discouraged if dye leaks from the nanoparticle core), or by 
chemically conjugating the dye to a polymer from which the particle is then 
formulated.18,19 Alternatively, a particle can be externally labeled by chemically 
conjugating fluorescent dye to functional groups on the particle surface. Internal labeling 
is preferable, as it is less likely to change the surface properties of the particle and alter 
the particle’s interaction with the specimens of interest. Internally labeled particles are 
also more photostable than externally labeled particles, in general. Many fluorescent 
dyes, with various chemical reactivities, are commercially available, though photostable 
dyes with high quantum yield and extinction coefficient should be selected whenever 
possible.27 The color of the fluorophore is another critical consideration. Biological 
specimens often have high autofluorescence, especially at shorter excitation wavelengths, 
which can interfere with particle detection and tracking. Thus, red or dark red fluorescent 
dyes may be advantageous. 
Although some research groups use microscopes specially designed and 
optimized for particle tracking,28 custom-built instrumentation is not required. In fact, 
particle tracking videos can be collected using hardware common in biomedical research 
labs and core facilities.29 For tracking of fluorescent particles, a widefield microscope 
with epifluorescence illumination and appropriate fluorescence filter sets is typically 
used. Objectives with large numerical aperture are ideal for high resolution particle 
tracking, since they collect more light, and tracking precision is proportional to the square 
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root of the number of photons emitted by a fluorescent particle.29 A high-powered light 
source, such as a mercury or metal halide arc lamp, should be used at its highest intensity 
setting. Then, the exposure time of the camera should be adjusted so that the image is 
neither under- nor over-saturated.29 This procedure will minimize particle tracking errors, 
as discussed in a later section. The microscope should be placed on a pneumatic 
vibration-isolation table to dampen any external vibrations, such as from footsteps and 
lab equipment. If the microscope stage is to be heated for the experiment, the temperature 
should be at equilibrium before collecting tracking videos, to prevent sample drift arising 
from expansion or contraction of microscope components. 
A sensitive (high quantum efficiency), low-noise camera is essential for precise 
particle tracking. The best choice is an electron-multiplying charge coupled device 
(EMCCD) camera, though scientific complementary metal oxide semiconductor 
(sCMOS) cameras can be used as well.30 The required frame rate will depend on the 
particle dynamics and research question. We have found 15 frames per second to be 
sufficient for studying transport of particles with diameters on the order of 100 nm in 
biological fluids and tissues, including mucus, vitreous, and brain tissue. Faster frame 
rates will be necessary for studying more rapid movement. If the exposure time can be set 
independently of the frame rate, the exposure should be no longer than necessary to 
achieve bright particle images. The rationale behind this guideline will be discussed in 
the section on errors in particle tracking. Although particle tracking videos are large files, 
it is important that the data be saved in a file format with lossless compression, since 
lossy compression discards data and worsens the tracking resolution.29 
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Two rules should be kept in mind when preparing specimens for particle tracking 
experiments. First, when possible, the chamber containing the specimen should be well 
sealed to minimize sample evaporation and convective flow during the experiment. 
Second, the particle concentration must be appropriate for visualizing and tracking 
individual particles. The average particle spacing must be larger than the average particle 
displacement from frame to frame, or else the paths of multiple particles will intermingle, 
making it difficult to accurately construct individual trajectories. If the particles are 
moving very rapidly, a faster frame rate can be used, but if that is not sufficient or 
feasible, a new specimen with lower particle concentration should be prepared. 
When performing particle tracking using unfamiliar hardware or software, it is 
helpful to track particles in a simple fluid with known viscosity, like water or glycerol, 
and verify that the diffusion coefficients can be measured to within a few percent of the 
value predicted by the Stokes-Einstein equation. Note well that simple systems give 
cleaner images than most biological systems; treat them as a best-case scenario. 
 
2.3. Extracting quantitative measurements from particle tracking videos 
2.3.1. Automated particle tracking using the Crocker and Grier algorithm 
There are two main stages to automated particle tracking: locating the spatial 
coordinates of particles in each frame of the movie, and then linking the coordinates 
through time into probable trajectories. Typically, tracking algorithms only require a 
video of particles and a few parameters, such as the apparent particle size and the 
maximum frame-to-frame particle displacement, as their inputs. As their output, they 
provide the particle trajectories (Figure 2.1), from which the mean square displacement 
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(MSD) can be calculated. Here, we describe the tracking algorithm of Crocker and Grier,2 
which has been widely used in fields such as colloid science, microrheology, biophysics, 
and, more recently, drug and gene delivery. The algorithm was originally implemented in 
the IDL programming language, but it has since been translated into various other 
languages, including Python, MATLAB, and C++. Numerous alternative algorithms have 
been developed for tracking particles, which we discuss later. 
In the algorithm of Crocker and Grier, particle coordinates are identified in four 
steps: 1) preparing the image using common image-processing techniques; 2) finding 
local maxima of brightness that may correspond to particles; 3) honing in on each 
candidate particle’s exact center with subpixel precision; and 4) discerning which of the 
candidates are true particles based on their morphology and measured brightness. The 
foundational paper2 explains these steps in precise mathematical detail. Here, we will 
conceptually describe each step in intermediate detail. 
The images are prepared using a spatial bandpass filter, which uses a Fourier 
transform of the image to eliminate all features with small-scale variation (e.g., camera 
noise) and large-scale variation (e.g., uneven lighting) (Figure 2.2). This effectively 
erases any objects in the background that are much smaller or much larger than the size 
of the particles. Next, all local maxima in the processed image are identified. (This is 
accomplished by taking the union of the image with its own morphological dilation.) If 
two or more local maxima are separated by a distance smaller than the particle diameter, 
only the brightest is retained. Then, the intensity-weighted centroid (“center of mass”) of 
each spot is iteratively refined. Finally, the neighborhood surrounding each spot is 
characterized by its total brightness, size, and eccentricity (deviation from circular shape). 
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Using these attributes, spots that correspond to actual particles can be distinguished – and 
the rest discarded – with minimal user input (Figure 2.3). For example, true particles tend 
to appear bright and circular. 
At this point, the x and y locations of particles in each frame are known. Next, the 
locations must be linked together across frames into particle trajectories. The algorithm 
robustly handles the complications of real trajectories: Particles are allowed to leave the 
frame, new particles are allowed to enter, and particles can even be tracked if they 
temporarily vanish and reappear nearby within a user-specified number of frames. If 
particles are well separated and moving slowly relative to the frame rate, the task of 
linking them is simple and unambiguous. If particles are dense and moving quickly, the 
linking algorithm assigns particles in a way that minimizes the total length of the links. 
This is grounded in the statistics of random walks; a Brownian particle is most likely to 
be found right where it was last seen. As the number of particles in view grows, resolving 
ambiguous networks is difficult. To simplify the problem, the algorithm requires the user 
to specify the maximum displacement allowed from one frame to the next. For each 
trajectory, the time-averaged mean squared displacement is calculated as a function of 
time scale, τ, as ⟨Δr2(τ)⟩ = ⟨[x(t + τ) - x(t)]2⟩ + ⟨[y(t + τ) - y(t)]2⟩, where the angled brackets 
denote the average over many starting times t. 
To process a set of videos with automated tracking, only a few minutes of user 
attention are required to input parameters and check that they are suitable. A standard 
computer will typically be able to process at least one video frame per second, though 
this depends on the density of particles (and therefore the number of calculations needed 
for a single frame) in the video, as well as the exact automated tracking algorithm and 
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implementation used. The code will output the trajectories in a text file, spreadsheet, or 
database. Subsequent data analysis will depend on the scientific question under 
investigation. We discuss data analysis strategies in Section 3.3.  
 
2.3.2. Sources of error and how to minimize them 
Understanding the precision and accuracy of particle localization is critical for 
conducting reliable particle tracking experiments. In fact, failure to recognize and 
account for imprecision and inaccuracy in tracking data can lead to misinterpretation.31,32 
Precision refers to uncertainty in location, and is defined as the standard deviation of the 
measured locations when a single stationary particle is imaged and localized multiple 
times. In contrast, accuracy describes whether the position estimates deviate from the true 
particle position with systematic bias.31,33 There is no limit on localization accuracy, but 
there is a limit on localization precision. 
Tracking resolution (i.e., localization precision) is different than microscope 
resolution, as classically defined. Microscope resolution is the minimum distance 
between two distinguishable points. Because of diffraction, the best resolution of a 
traditional light microscope is approximately half the wavelength of visible light, or 
roughly 250 nm.34 However, using an appropriate algorithm, it is possible to localize the 
center of an isolated particle or point source to better than the diffraction-limited 
resolution.30,35 Thus, researchers can routinely track particles with a lateral spatial 
precision of tens of nanometers or less using a standard light microscope.29 
Tracking precision is subject to both fundamental and experimental limitations. 
The fundamental limitation is photon noise: a particle can emit only a finite number of 
17 
 
photons during the exposure time, and the number of photons that arrive at a given 
location on the camera detector in a certain time interval is stochastic, following a 
Poisson distribution.36 Consequently, there is statistical uncertainty in locating the 
particle from its image (Figure 2.4). The size of this uncertainty is inversely proportional 
to the square root of the number of detected photons.29,34 Experimental limitations related 
to detector and specimen properties can also degrade localization precision. Detector 
pixelation makes it impossible to determine the exact position where a photon arrives 
within a pixel. Detector noise, including dark current (thermally-induced electrons in the 
detector) and readout noise (errors in reading the number of photoelectrons built up in a 
pixel), can also interfere with particle localization.31,34 Detector noise is greatly reduced 
in high-performance, cooled, EMCCD cameras. Specimen autofluorescence and out-of-
focus background fluorescence can also reduce localization precision and accuracy, 
which can be an issue when tracking particles in a thick biological specimen using 
standard epifluorescence illumination. Image processing can remove some, but not all, of 
this background.31 Finally, it is important to note that lateral localization precision of 
fluorescent particles is best for particles located in the focal plane – where the particle 
image is smallest, brightest, and closest to a Gaussian curve in shape – and decreases 
with increasing distance from the focal plane.31,37 
The inability to exactly localize particles, even when they are stationary, is one 
source of error in particle tracking. This type of error has been referred to as static error, 
localization error, or random error.25,29,38 Static error adds a constant offset to the MSD, 
as derived previously:25,38 In two dimensions, MSDmeasured = MSDtrue + 4σ2, where σ is 
the localization precision. A perfectly immobilized particle will have a true MSD = 0 for 
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all time scales (τ), but because of static error, the actual measured MSD will be a non-
zero constant, MSD = 4σ2. For pure Brownian motion in two dimensions, the true MSD 
is MSD(τ) = 4Dτ, but with static error, MSD(τ) = 4Dτ + 4σ2.25,29 However, in most 
particle tracking experiments, the true underlying MSD is not known a priori, so it may 
not be immediately evident which component of the measured MSD is “true” and which 
is artifact. 
Additional error is introduced when the particles are moving (Figure 2.4), as is 
typical in particle tracking experiments. Images cannot be collected instantaneously, and 
thus require a finite exposure time. If a particle moves substantially during this exposure 
time, a blurred spot will be recorded, representing the time integral of the particle’s 
location. Particle motion during the exposure time reduces the observed MSD at short 
times for randomly diffusing particles, as they tend to revisit previously explored 
regions.29,39 This effect has been called dynamic error.38 In addition, particle motion 
increases static error, because motion blur reduces localization precision by roughly two-
fold under typical experimental conditions, as compared to stationary particles.40 
Static and dynamic error can alter the measured MSD, and can thus introduce 
inaccuracies when using the MSD to calculate diffusion coefficients and viscoelastic 
moduli. Static error alone adds a constant offset to the MSD, which flattens the MSD at 
short time scales on a log-log plot, and makes diffusive motion appear sub-diffusive.25 
Dynamic error, by itself, decreases the MSD at short time scales, which makes diffusive 
motion appear super-diffusive. Since static and dynamic error act in opposite directions, 
various scenarios are possible when both errors are present.38 Depending on which type 
of error is larger, one effect may dominate, or occasionally, the two effects may largely 
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cancel each other.38 Both sources of error are more pronounced at short time scales, when 
the true MSD is smaller. 
Prior to beginning a particle tracking experiment, researchers should consider 
how to minimize errors. Choosing bright particles, a microscope objective with large 
numerical aperture, and a sensitive camera with low noise will increase signal-to-noise 
ratio and reduce static error. Choosing image acquisition settings, however, requires a 
tradeoff between between static and dynamic error (Figure 2.4). Longer exposure time 
boosts the signal, which, all else being equal, decreases static error. Unfortunately, longer 
exposure time increases dynamic error as well. The only way to reduce dynamic error is 
to use an exposure time that is small compared to the frame interval.29,38 A compromise is 
to use the longest exposure time possible without introducing large dynamic error. For 
Brownian motion, an exposure time no longer than one quarter the frame interval will 
cause dynamic error of <10% at the shortest time scale, and smaller dynamic error at 
longer time scales.29 
Dynamic error is difficult to correct after an experiment, because it is time-
dependent and also depends on the underlying type of motion, which is often unknown.41 
Static error is simpler to quantify and correct for, since static error adds a constant offset 
to MSD regardless of the nature of particle motion. Static error can be estimated by 
tracking particles fixed to a coverslip under signal-to-noise conditions similar to those of 
the experiment. However, this simple approach may not precisely mimic the background 
noise in the experiment, nor the effect that motion blur has on static error. An alternative 
method has recently been proposed for measuring localization precision of moving 
particles, though this technique requires a custom microscope configuration.40 
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To conclude this discussion, we consider the following question: How much do 
researchers conducting particle tracking experiments need to worry about static and 
dynamic error? The answer depends both on the system under investigation and on the 
desired analysis. If the research objective is to precisely quantify diffusion coefficients or 
viscoelastic moduli, or to fit the data to a model, it is critical to consider static and 
dynamic error to ensure proper analysis – especially if the imaging conditions were not 
ideal. In particular, higher spatial and temporal resolution are needed to accurately study 
particle motion at short times scales, where the MSD is smaller and the errors 
proportionally larger. However, if the research objective is to qualitatively compare the 
transport rates of two types of drug delivery nanoparticles with very different behavior, 
such as mobile and immobile, moderate errors require less thorough examination and are 
unlikely to alter the final conclusion. 
 
2.3.3. Assessment of other algorithms for particle localization 
Previously, we detailed the widely used automated tracking algorithm of Crocker 
and Grier. Many other research groups have developed their own tracking algorithms. In 
a recent competition with 14 entrants, no single algorithm proved to be universally best.42 
Rather, algorithm performance varied depending on characteristics of the experimental 
system under investigation, such as the type of particle motion, signal-to-noise ratio, and 
density of particles in the field of view. Therefore, we now outline other select 
approaches for particle localization and trajectory linking, and discuss their advantages 
and disadvantages. Regardless of the method chosen, proper algorithm implementation 
and careful choice of parameters are critical for minimizing error.42 
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There are two main classes of algorithms for locating particle positions in two 
dimensions: those using model fitting and those not. The model fitting methods fit the 
particle image to a mathematical model based on the point spread function (PSF). The 
PSF is the blur pattern formed by diffraction when a point source of light is imaged.30 
Fitting is accomplished by varying the model parameters, including the x and y spatial 
coordinates, and finding the best fit using a least squares method or maximum likelihood 
estimation (MLE). The MLE technique can, in theory, approach the best achievable 
localization precision.30,36 However, a major limitation is that fitting methods require an 
estimate of the PSF, and for the MLE approach, of the camera noise as well.30 The PSF 
for a point source that is in focus can be modeled by a Gaussian, though this is not exact, 
especially at the tails. Furthermore, modeling the particle image becomes more complex 
when the particle is out of focus, or if the particle is too large to be considered a point 
source, or if the image is asymmetric.31-33 Another limitation is that fitting methods tend 
to be computationally intensive and slow.32 
Particles can also be localized by methods that do not use model fitting. The 
centroid technique, used by Crocker and Grier, is perhaps the simplest and most widely 
used non-fitting method. Such algorithms do not require models of the PSF, and thus may 
be well suited for experimental conditions that distort the PSF, including rapidly moving 
particles, heterogeneous biological specimens, and imaging in deep in tissue,30 all of 
which are common in drug and gene delivery experiments. Indeed, although Gaussian 
fitting was reported to perform better than the centroid method at localizing immobilized 
particles, especially at low signal-to-noise ratios,33 a recent study found that the centroid 
method is more reliable for moving particles.40 A different model-independent particle 
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localization method, which was recently developed, localizes the particle using radial 
symmetry.32 The radial symmetry method can be envisioned by drawing lines orthogonal 
to contours of constant intensity in the particle image. The point closest to the 
intersections of these lines is an estimate of the particle center. This method performed 
better than the centroid method, and nearly as well as Gaussian fitting using MLE, in one 
report.32 In the same study, radial symmetry was 100 times faster (and the centroid 
method 1,000 times faster) compared to Gaussian fitting.32 However, we note that radial 
symmetry is a new technique that should be further studied and tested under additional 
experimental conditions. Development of new algorithms for localizing particles rapidly 
and precisely continues to be an active area of research, motivated recently by 
localization-based super-resolution microscopy techniques such as PALM/STORM, 













Figure 2.1. Trajectory maps from particle tracking. 
(a) 100 nm PS-PEG particles in an inhomogeneous biological specimen, CF sputum, as 






Figure 2.2. Image preparation using a spatial bandpass filter. 
The bandpass filter reduces noise and background. Figures show image of 100 nm 
yellow-green fluorescent polystyrene (PS) particles in a CF sputum sample (A) before 






Figure 2.3. Selecting true particles using brightness, size, and eccentricity. 
True particles are distinguished from spurious ones based on their brightness, size, and 
eccentricity. A video of fluorescent 500 nm polystyrene particles diffusing in water, 
imaged with a 1.46 N.A. oil-immersion objective, was analyzed. For such particles, a plot 
of particle radius vs. brightness (A) reveals that spurious particles (noise) are dim, 
whereas true particles are brighter and form a characteristic cluster, which is outlined by 
the blue polygon. The shape of this cluster is a consequence of the optics. Particles 
located at the focal plane are the brightest and most compact, while particles above and 
below the focal plane appear larger and less bright, forming the two prominent curved 





candidate particles based on radius and brightness. The next step is to filter particles 
based on their eccentricity. (C) A plot of eccentricity (smaller number means more 
circular in shape) vs. brightness shows that most spots, except the dimmest ones, have 
eccentricity < 0.2. These are the true particles, and they are selected with the blue 
rectangle. (D) The particles identified on the same frame of the movie as in (B) after 





Figure 2.4. Demonstration of localization precision and static error. 
 (A-C) Three bright particle images (~2,500 photons each). The true particle centers are 
at the center of each image. The particle images are computer-generated with photon 
noise, per the method of Thompson (2002), but no camera or background noise. (D) Plot 
of measured particle centers, calculated from 100 such low-noise images by the centroid 
method. Scale bar represents half a pixel. (E-G) Three dim particle images (~100 photons 
each). The true particle centers are at the center of each image. (H) Plot of measured 
particle centers, calculated from 100 such high-noise images by the centroid method. 


















Figure 2.5. Demonstration of the tradeoff between static and dynamic error. 
Both A and B are images of fluorescent 100 nm particles diffusing in water. In A, the 
exposure time was 2 ms, while in B, the exposure time was 67 ms; the imaging 
conditions were otherwise identical. Noise is more pronounced in A compared to B. 
However, the particle images are compact and circular in A, whereas considerable motion 
blur is evident in B. 
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3. NANOPARTICLE DIFFUSION IN RESPIRATORY MUCUS FROM 
HUMANS WITHOUT LUNG DISEASE1 
 
3.1. Introduction 
Mucus lines the conducting airways, protecting the respiratory epithelium from 
the external environment. The respiratory mucus barrier comprises two layers: The gel 
layer, rich in secreted macromolecules, which is continuously cleared by ciliary beating, 
and the periciliary layer, consisting of macromolecules tethered to the airway surface, 
which facilitates ciliary activity.15 A major role of the respiratory mucus gel is to trap 
inhaled particles so they can be swept from the airways by mucociliary clearance, thereby 
defending the lungs against pathogens and toxic materials.13 However, it is not known 
what size particles are trapped, or how particle surface chemistry affects mobility, in the 
airway mucus gel layer of humans without respiratory disease.46 Airway mucus is 
difficult to collect and analyze because individuals with healthy respiratory systems 
generally cannot spontaneously expectorate it, and the mucus gel layer is only a few to a 
few tens of micrometers thick.13,47 Yet measuring the permeability of this mucus gel is 
essential for understanding how effectively it protects the lungs from continuously 
inhaled pathogens and environmental particulates. Studying the interaction between 
respiratory mucus and nanoparticles may also elucidate design criteria for inhaled 
therapeutic nanoparticles to treat diseases such as lung cancer; these particles must 
penetrate the mucosal barrier to avoid rapid clearance and achieve the pharmacokinetic 
profile requisite for effective therapeutic outcomes.48 Finally, characterizing respiratory 
mucus from humans without pulmonary disease may provide a benchmark against which 
                                                 
1 This chapter appears in Schuster, BS, Suk, JS, Woodworth, GF and Hanes, J (2013). Nanoparticle diffusion in respiratory mucus 
from humans without lung disease. Biomaterials 34: 3439-3446. 
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to compare respiratory secretions from patients with diseases that affect the airways, 
including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis 
(CF).  
Nanoparticle diffusion has previously been measured in a variety of human mucus 
secretions, including cervicovaginal (CV) mucus,49 CF sputum,50,51 and chronic 
rhinosinusitis mucus.52 Conventional, uncoated polystyrene particles have hydrophobic 
surfaces that adhere to hydrophobic domains on mucin fibers – the long, entangled 
glycoproteins responsible for the mucus gel structure.14 We discovered that coating 
polystyrene nanoparticles with a dense layer of low molecular weight polyethylene glycol 
(PEG) minimizes particle adhesion to mucus.49 PEG minimizes protein adhesion at 
biomaterial surfaces because the hydrated PEG layer resists release of water molecules 
and compression.16 Using PEG-coated particles, we were able to probe the mucus 
microstructure.53 We found that PEG-coated particles as large as 200 nm in diameter can 
penetrate sputum freshly expectorated by CF patients,50 and PEG-coated particles as large 
as 500 nm can penetrate CV mucus collected from healthy women,49 whereas 
comparably sized uncoated particles are immobilized by the mucus mesh. Tracking the 
motion of individual PEG-coated and uncoated particles in fresh, minimally diluted 
mucus samples offers several advantages compared to traditional approaches for studying 
mucus gel structure and permeability. Electron microscopy, for instance, requires fixation 
methods that can change the mucus structure.14 Transport studies using only 
conventional, uncoated polystyrene particles cannot distinguish between adhesive and 
steric contributions to particle trapping. Finally, bulk diffusion measurements do not 
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reveal transport rates at the single-particle level, and thus cannot identify particle 
subpopulations of interest, such as fast-moving outliers. 
Mucus secretions from various moist epithelia are similar in overall properties – 
they are viscoelastic gels comprised of water and mucins, as well as salts, non-mucin 
proteins, and lipids – but their exact biochemical compositions, clearance rates, and 
microbiota differ with anatomical site and disease state.13 These factors alter the mucus 
microstructure and permeability, and motivate the analysis of mucus from various tissues 
and conditions. Here, our aim was to study normal human airway mucus, which we 
define as minimally manipulated airway mucus from individuals without respiratory 
disease. As a model for normal airway mucus, we collected the mucus from endotracheal 
tubes of patients without respiratory comorbidities who underwent elective, non-
cardiothoracic surgery, as previously described.54 This collection method is noteworthy 
because it imposes no additional burden on the patient, and in contrast to bronchiolar 
lavage or to sputum induction using nebulized hypertonic saline, it minimizes sample 
dilution and salivary contamination.54,55 We performed scanning electron microscopy to 
visualize the mucus samples and conducted biochemical assays to analyze their basic 
composition. To elucidate the physicochemical properties of nanoparticles that govern 
their transport rates in normal airway mucus, we measured the mobility of PEG-coated 
and uncoated 100, 200, and 500 nm polystyrene particles in fresh mucus samples using 
high-resolution fluorescence microscopy and multiple-particle tracking analysis. We 
further investigated the mucus gel structure and the barrier it poses to nanoparticle 
diffusion by comparing the bulk rheological properties of respiratory mucus, as measured 
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3.2.1. Mucus sample collection 
Human airway mucus samples were collected in accordance with a protocol 
approved by the Johns Hopkins Medicine Institutional Review Board (study number 
NA_00038606).  Samples were collected by the endotracheal (ET) tube method, as 
previously described.54,56 Patients who required intubation as part of general anesthesia 
for elective, non-cardiothoracic surgery at the Johns Hopkins Hospital were identified. 
Only patients with no cardiopulmonary or respiratory comorbidities and no smoking 
history were included in this study. At the end of surgery, the ET tube was removed from 
the patient, and the distal 10 cm portion, including the balloon cuff, was cut and placed in 
a 50 mL centrifuge tube. The specimens were then spun at 1000 rpm (220 × g) for 30 s, 
yielding an average mucus volume of 0.5 mL. Mucus with visible blood contamination 
was not included in the analysis. Mucus samples were stored at 4 °C and analyzed within 
24 hours of collection, excluding portions for the mucin and DNA assays, which were 
frozen at -20 °C until use. The results presented here are from male and female patients; 
the mean patient age was 56 years, with standard deviation 17 years. 
 
3.2.2. Rheology of respiratory mucus 
Bulk rheological properties of airway mucus were measured using a strain-
controlled rheometer (RFS3; TA Instruments) with cone-and-plate geometry (cone 
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diameter 25 mm and angle 0.1 rad). All measurements were conducted at room 
temperature in a humidified chamber. Oscillatory tests, performed at small strain 
amplitudes to minimize shear damage to the mucus samples, were used to measure the 
frequency-dependent elastic modulus, 𝐺′(𝜔), and viscous modulus, 𝐺′′(𝜔), of the 
mucus.57 (The elastic and viscous moduli, respectively, are the in-phase and out-of-phase 
components of stress induced in the material, divided by the magnitude of the applied 
strain.) After the mucus sample was loaded onto the rheometer, it was allowed to 
equilibrate for five minutes. Then, the linear viscoelastic region, for which the viscous 
and elastic moduli are independent of strain amplitude,58 was determined by conducting 
strain amplitude sweeps from 0.2 to 10% strain at frequencies of 1, 6.28, and 100 rad/s. 
Based on the strain sweep tests, 1% strain was determined to be within the linear 
viscoelastic region, and was thus used for the frequency sweep test (from 0.1 to 100 
rad/s). 
 
3.2.3. Determination of mucin, DNA, and total solids content 
Mucin concentration was determined based on the reaction of 2-cyanoacetamide 
(Sigma-Aldrich) with O-linked glycoproteins, as previously described.51,59 Mucus 
aliquots were diluted 20-fold and homogenized by vortexing for at least 15 min. Then, 50 
µL of this suspension was mixed with 60 µL of an alkaline solution of 2-cyanoacetamide 
(200 µL of 0.6 M 2-cyanoacetamide added to 1 mL of 0.15 M NaOH). The mixture was 
incubated at 100 °C for 30 min, after which 0.5 mL of 0.6 M borate buffer, pH 8.0, was 
added to it. Fluorescence intensity was measured at excitation and emission wavelengths 
of 340 and 420 nm, respectively. Mucin concentrations were calculated by comparing the 
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fluorescence intensity readings to a standard curve generated using known concentrations 
of mucin from bovine submaxillary gland (Sigma-Aldrich).  
A fluorimetric assay was also used to measure DNA concentration, based on the 
reaction of 3,5-diaminobenzoic acid dihydrochloride (DABA; Sigma-Aldrich) with 
DNA.51 Mucus aliquots were diluted 5-fold and homogenized by vortexing for at least 15 
min. Then, 30 µL of this suspension was reacted with 30 µL of 20% wt/vol DABA 
solution. After incubating for 1 h at 60 °C, 1 mL of 1.75 M HCl was then added to stop 
the reaction. The fluorescence was measured at excitation and emission wavelengths of 
400 and 520 nm, respectively. DNA concentrations were calculated with reference to a 
standard curve generated using known concentrations of DNA from salmon testes 
(Sigma-Aldrich). 
The total solids content of mucus was determined by freeze-drying. Mucus 
samples were frozen in liquid N2 and placed in a lyophilizer (FreeZone 4.5 Plus; 
Labconco) for at least 12 h to extract water from the samples. The ratio of mucus mass 
before versus after lyophilization is the total solids content.  
 
3.2.4. Scanning electron microscopy  
Respiratory mucus samples were prepared for scanning electron microscopy 
(SEM) based on a protocol previously used for CV mucus and CF sputum.51,60 Mucus 
samples were fixed for 1 h in 2% glutaraldehyde in 100 mM sodium cacodylate buffer, 
pH 7.2, containing 3 mM CaCl2. The samples were then rinsed in buffer and postfixed in 
1% OsO4 in 100 mM sodium cacodylate buffer for 1 h on ice in the dark. Following a 
brief rinse with distilled water, samples were stained with 2% uranyl acetate for 1 h and 
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then dehydrated through a graded series of ethanol solutions. Upon complete dehydra-
tion, samples were soaked in a 50:50 mixture of ethanol and hexamethyldisilazane 
(HMDS), followed by pure HMDS. Mucus samples were then dessicated under vacuum 
overnight. The samples were attached to aluminum stub mounts via carbon adhesive tabs 
(Ted Pella), and then coated with 20 nm of AuPd with a sputter coater (Desk III; Denton 
Vacuum). The samples were imaged with a field-emission scanning electron microscope 
(LEO 1530 FESEM; Zeiss) operating at 1 kV. 
 
3.2.5. Nanoparticle preparation and characterization 
Fluorescent, carboxylate-modified polystyrene spheres (PS-COOH) sized 100, 
200, and 500 nm in diameter were purchased from Molecular Probes. The surface density 
of carboxyl groups on the particles, calculated using data provided by the manufacturer, 
ranged from 3 to 8 COOH/nm2 depending on the lot. PEG-coated particles were prepared 
by covalently modifying the PS-COOH particles with 5 kDa methoxy-PEG-amine 
(Creative PEGWorks) using carbodiimide coupling chemistry.18 Briefly, 100 μL of PS-
COOH particle suspension, supplied by the manufacturer as 2% solids, were washed and 
resuspended to 4-fold dilution in ultrapure water in a 1.5 mL microcentrifuge tube. PEG 
was added to the particle suspension in excess (2-fold excess for the 100 nm particles and 
5-fold excess for the 200 and 500 nm particles), based on the number of carboxyl groups 
on the particles. After mixing to dissolve the PEG, N-hydroxysulfosuccinimide sodium 
salt (sulfo-NHS; Sigma-Aldrich) was added to the tube, followed by 600 uL of 200 mM 
borate buffer, pH 8.2, and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC; Invitrogen). NHS and EDC concentrations were 10 mM and 6 mM, 
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respectively. Particles suspensions were placed on a tube rotator for 4 hours, then 
centrifuged and washed with ultrapure water. Particles were resuspended in ultrapure 
water to the original concentration. Aliquots for particle transport experiments were 
diluted with ultrapure water to obtain concentrations appropriate for tracking individual 
particles. Particle suspensions were stored at 4 °C until use.  
The surface density of PEG on PS-PEG particles prepared according to this 
protocol was recently measured to be 0.09 PEG/nm2, using a nuclear magnetic resonance 
(NMR) method, as reported by our lab.18 Particle size and zeta-potential were measured 
by dynamic light scattering and laser Doppler anemometry, respectively, using a 
Zetasizer Nano ZS90 (Malvern Instruments), which has a 90° scattering angle. Both size 
and zeta-potential were measured at 25 °C, with the particles suspended in phosphate 
buffered 10 mM NaCl solution, pH 7.4.  
 
3.2.6. Multiple particle tracking in respiratory mucus 
Nanoparticle transport in airway mucus was studied by multiple particle tracking 
(MPT). The particle suspensions were added to mucus samples at a final dilution of 4% 
vol/vol in custom-made microscopy chambers. After gently stirring the samples, the 
chambers were sealed to prevent sample dehydration, then incubated for 1.5 h. Particle 
motion in the mucus samples was observed at room temperature using an inverted 
epifluorescence microscope (Axio Observer; Zeiss) with a 100x/1.46 NA oil-immersion 
objective. Movies were collected for 20 s at a temporal resolution of 67 ms using an 
EMCCD camera (Evolve 512; Photometrics). Movies were analyzed with MetaMorph 
software (Molecular Devices) to extract the x and y positions of particle centroids over 
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time. At least 100 PS-COOH and PS-PEG particles of each size were tracked for at least 
50 frames in each of five mucus samples. For each trajectory, the time-averaged mean 
squared displacement (MSD) was calculated as a function of time scale, τ, as ⟨Δr2(τ)⟩ = 
⟨[x(t + τ) - x(t)]2⟩ + ⟨[y(t + τ) - y(t)]2⟩. The tracking resolution, determined by tracking 
particles immobilized to glass with a strong adhesive,61 was determined to be 10 nm 
(substantially smaller than the diameter of the particles). Based on the SEM images, 
airway mucus may be assumed to be isotropic (though not homogeneous), so the 2-
dimensional MSD measured here by MPT equals two-thirds of the 3-dimensional MSD. 
The ensemble-averaged MSD (⟨MSD⟩) for all particles of a given type in a given mucus 
sample was calculated by taking the geometric mean of the individual particles’ time-
averaged MSDs. We fit the ⟨MSD⟩ data to the equation ⟨MSD⟩ = kτα to obtain α, which is 
a measure of the extent of impediment to particle diffusion (α = 1 for pure Brownian 
motion and α < 1 for subdiffusion). This was accomplished by calculating the slope of 
log(⟨MSD⟩) vs. log(τ) using the least-squares method. Additional information on MPT 
measurements is available in review articles.61,62 
 
3.2.7. Particle tracking microrheology analysis 
 Particle tracking microrheology analysis was performed by applying the 
generalized Stokes-Einstein relation (GSER) to the PS-PEG particle MSD data. The 
GSER relates the thermal motion of particles to the viscoelastic moduli of the material 
environment they probe. The unilateral Laplace transform of the MSD, ⟨𝛥?̃?2(𝑠)⟩, is 
related to the viscoelastic spectrum of the material, 𝐺�(𝑠), according to the GSER by 
𝐺�(𝑠) = 2kB𝑇 [3𝜋𝑎𝑠 ⟨𝛥?̃?2(𝑠)⟩]⁄ . Here, kB is Boltzmann’s constant, T is the absolute 
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temperature, a is the particle radius, and s is the complex Laplace frequency. This can be 
used to find the complex modulus, 𝐺∗(𝜔) = 𝐺′(𝜔) +  𝑖𝐺′′(𝜔), as detailed elsewhere.63,64 
In this way, the displacements of the particles can be used to calculate the microscopic 
viscoelasticity of the environment they probe. The viscoelastic response can 
alternatively65 be interpreted as a complex viscosity, 𝜂∗(𝜔), whose magnitude is defined 
as |𝜂∗(𝜔)| = |𝐺∗(𝜔)| 𝜔⁄ . Complex viscosity thus incorporates both viscous and elastic 
contributions. In the limiting case, for a purely viscous Newtonian liquid such as water, 
the complex viscosity equals the standard steady shear viscosity.  
 
3.2.8. Viscosity of mucus interstitial fluid 
The viscosity of mucus interstitial fluid was determined by centrifuging mucus 
samples for 1 h at 21,000 × g, removing the supernatant, and then measuring the 
supernatant viscosity by particle tracking microrheology (we confirmed that these 
supernatant viscosity measurements did not depend on probe particle size). 
 
3.2.9. Statistical analysis 
Statistical analysis (for Figure 3.6) was performed by one-way analysis of 
variance (ANOVA) using logarithmically transformed data. Subsequent multiple 
comparison tests were performed using Tukey’s HSD procedure. Analysis was conducted 
using the Statistics Toolbox in MATLAB R2012a (MathWorks). Differences were 





3.3.1. Bulk rheology  
To characterize the bulk material properties of respiratory mucus, we measured 
the viscoelastic moduli of mucus samples (n = 5) using a cone-and-plate rheometer. We 
determined from strain sweep tests that 1% strain is within the linear viscoelastic region 
(Figure 3.1A). We then measured the frequency-dependent viscoelastic moduli at 1% 
strain and found that the elastic modulus, 𝐺′(𝜔), exceeded the viscous modulus, 𝐺′′(𝜔), 
over the 3 decades of frequency tested (Figure 3.1B). A frequency of ω = 1 rad/s is 
traditionally used in mucus rheology studies to approximate the low shear rates of 
mucociliary clearance 66,67. The ratio of the viscous to elastic modulus, tan(𝛿) =
𝐺′′(𝜔)/𝐺′(𝜔), was 0.30 at ω = 1 rad/s; this corresponds to a phase angle of δ = 17°. 
Materials with 0 < 𝐺′′/𝐺′ < 1, or equivalently 0° < 𝛿 < 45°, are categorized as 
viscoelastic solids. The viscous and elastic moduli exhibit a weak frequency dependence, 
with log (𝐺′) and log (𝐺′′) both having slopes around 0.15 when plotted against log (𝜔). 
Overall, this rheological signature is characteristic of a crosslinked gel, as expected.67  
 
3.3.2. Biochemical analysis 
To assess mucus sample quality and composition, we conducted basic 
biochemical analysis. The total solids content of airway mucus was 6.9 ± 2.8% (n = 13). 
The measured mucin content ranged from 8 to 22% of the total solids, corresponding to a 
mucin content of 0.6 to 1.4 %, while DNA comprised less than 1% of the total solids on 




3.3.3. Microstructure of respiratory mucus 
We imaged airway mucus using scanning electron microscopy, which visually 
confirmed that the mucus samples have a meshwork architecture (Figure 3.2). In the 
SEM images, pores in the mucus mesh ranged from tens to hundreds of nm in diameter, 
with many pores smaller than 100 nm; we note, however, that SEM sample preparation 
likely contracts the mucus microstructure.14 The fibers appeared to be randomly oriented, 
which suggests that the mucus samples are isotropic. The SEM images of normal airway 
mucus were similar in overall appearance to previously published images of CF 
sputum.51,68  
 
3.3.4. Transport of particles in respiratory mucus 
We compared the thermally-driven motion of PEG-coated polystyrene 
nanoparticles (PS-PEG) to that of conventional carboxylate-modified PS nanoparticles 
(PS-COOH) in fresh human respiratory mucus using multiple-particle tracking (MPT). 
The dense PEG layer on the PS-PEG particles was confirmed by their near-neutral 
surface charge, compared to the highly negative surface charge of the PS-COOH particles 
(Table 3.1). We have also recently quantified the PEG density using an NMR-based 
method.18 The 100 nm diameter PS-COOH particles exhibited hindered trajectories in 
airway mucus, and the 200 and 500 nm PS-COOH particles were essentially immobilized 
(Figure 3.3A, C and E). In contrast, the 100 and 200 nm PS-PEG particle trajectories 
were more diffusive (Figure 3.3B and D). The 500 nm PS-PEG particles exhibited 




To quantify these differences, we calculated the mean squared displacements 
(MSDs) of at least 100 individual particles of each particle type in each mucus sample (n 
= 5). At a time scale (τ) of 1 s, the geometric ensemble-averaged MSD (⟨MSD⟩) of 100 
and 200 nm PS-PEG particles was 14-fold and 33-fold greater, respectively, compared to 
the 100 nm and 200 nm PS-COOH particles (Figure 3.4). However, the ⟨MSD⟩ of the 500 
nm PS-PEG particles was similar to that of the 500 nm PS-COOH particles for all time 
scales. At a time scale of 1 s, the 100 and 200 nm PS-PEG particles were slowed only 26- 
and 41-fold, respectively, compared to their theoretical diffusivities in water, as 
calculated with the Stokes-Einstein equation. In contrast, the 100 and 200 nm uncoated 
particles were slowed 390- and 1600-fold, respectively, compared to their theoretical 
diffusivities in water. The 500 nm particles, both PS-COOH and PS-PEG, were slowed 
more than 500-fold compared to their theoretical diffusivities in water (Table 3.1).  
To further assess the extent to which normal airway mucus hinders particle 
motion, we fit the ensemble-averaged MSDs to ⟨MSD⟩ = kτα and extracted α, the 
anomalous diffusion exponent. For pure Brownian motion in a viscous liquid, α = 1; for 
anomalous subdiffusion in complex environments over short time scales, α < 1, with 
smaller α indicating more hindered particle motion.62 The value of α for 100 and 200 nm 
PS-PEG particles was 0.88 and 0.82, respectively, while for the 100 and 200 nm PS-
COOH particles, it was 0.68 and 0.54, respectively (Table 3.1). The α values were only 
0.59 and 0.54 for 500 nm PS-PEG and PS-COOH particles, respectively. 
Fast-moving particles are of particular interest, as they are more likely to 
penetrate the heterogeneous mucus layer quickly enough to reduce their removal by 
mucociliary clearance and approach the underlying epithelium. In addition to ensemble-
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averaged transport rates, MPT also provides individual particle data, which can be 
represented in a histogram of individual particle MSDs (Figure 3.5; these results are 
presented at τ = 3 s to facilitate comparison with the 3 s long trajectories in Figure 3.3). 
Particles with MSDs less than 0.1 µm2 at a time scale of 3 s appeared immmobile in our 
time-lapse videos. (We note that longer tracking videos would be valuable to confirm that 
these particles are immobile over timescales well beyond 3 s.) The MSD value of 0.1 µm2 
at τ = 3 s is approximately 500-fold lower than that of a 100 nm particle diffusing in 
water. If we define particles below this cutoff as immobile and above it as mobile, we 
find 84%, 75%, and 8% of 100, 200, and 500 nm PS-PEG particles, respectively, were 
mobile. The 100 nm PS-COOH particles did have a sizable mobile fraction by the above 
definition, over 42%, whereas only 11% of 200 nm and 5% of 500 nm PS-COOH 
particles were mobile. 
  
3.3.5. Micro- vs. macroscopic rheology 
To deepen our understanding of the mucus gel structure and the barrier it poses to 
different sizes of PEG-coated particles, we compared the macroscopic (bulk) rheological 
properties of respiratory mucus, as measured using a cone-and-plate rheometer, with the 
microscopic rheological properties, as measured by particle tracking microrheology 
(PTM). To facilitate this comparison, the values we report here are |𝜂∗(𝜔)|, the 
magnitude of the complex viscosity, at ω = 1 rad/s. At the bulk level, respiratory mucus 
had a complex viscosity magnitude more than 13,000 times that of water. In contrast, the 
measured viscosity of mucus interstitial fluid was approximately 3 times that of water 
(Figure 3.6), in good agreement with a previous study on CF sputum.69 The 100 and 200 
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nm PS-PEG particles experienced viscosities only 16- and 38-fold higher than that of the 
mucus interstitial fluid, respectively, and more than 250- and 100-fold lower than the 
bulk viscosity (Figure 3.6). In contrast, the 500 nm PS-PEG particles experienced an 
average viscosity more than 1000 times greater than that of the mucus interstitial fluid, 
and only 4-fold lower than the bulk viscosity of mucus.  
 
3.4. Discussion 
 In this study, we explored the barrier properties of human respiratory mucus 
collected from individuals without lung disease. We found that polymeric nanoparticles 
as large as 200 nm, if densely coated with low molecular weight PEG, can rapidly diffuse 
through respiratory mucus. This finding will help guide the design of inhaled therapeutic 
nanoparticles – including drug, gene, and vaccine carriers – which offer the potential for 
increased efficacy and reduced side effects compared to traditional approaches for 
treating and preventing respiratory disease. To be maximally effective, inhaled 
chemotherapy-loaded nanoparticles for lung cancer70 and nanoparticle-based vaccines for 
tuberculosis and influenza71,72 may need to achieve broad coverage throughout the 
airways and avoid rapid clearance by the mucociliary escalator.48 We recently reported 
that mucus-penetrating nanoparticle formulations can improve the distribution, retention, 
and efficacy of vaginally administered drugs.19 Likewise, particles that can rapidly 
penetrate airway mucus may achieve reduced clearance and improved airway 
distribution, retention, and pharmacokinetic profile. The present work also enhances 
understanding of the barrier properties of airway mucus to inhaled environmental 
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particles, such as viruses and particulate matter pollution, both of which are major global 
health risks.73  
The findings in this study suggest that airway mucus is a selectively permeable 
barrier, whose barrier properties depend upon both particle size and adhesiveness. Small, 
PEG-coated particles exhibit enhanced transport in airway mucus compared to similarly 
sized uncoated particles because the dense PEG coating reduces particle adhesion to the 
mucus network, permitting the particles to diffuse more freely.49,50,53 The low viscosities 
experienced by 100 and 200 nm PEG-coated particles indicate that these particles resist 
muco-adhesion and furthermore are small enough to diffuse through fluid-filled openings 
in the mucus network, so they are less sensitive to the bulk rheological properties of the 
mucus. To these particles, on average, the mucus barrier is a low-viscosity liquid. In 
contrast, the 500 nm particles, even with PEG coatings, experience significantly larger 
viscosities, approaching the mucus bulk viscosity. This is most likely because their large 
size relative to the mucus mesh size precludes the particles from readily percolating 
through the mucus gel. Particles that are large relative to the mucus mesh spacing, 
similarly to particles that firmly adhere to mucus, are sensitive to the elasticity of the 
biopolymer network and its solid-like bulk rheology. 
Our finding that PEG-coated particles as large as 200 nm in diameter can diffuse 
in respiratory mucus appears to conflict with our visual analysis of SEM images, in 
which the majority of pores appeared to be smaller than 100 nm. As previously 
documented, this discrepancy is likely caused by alteration of the mucus network during 
SEM sample preparation, which entails fixation and dehydration of the mucus; quick 
freezing is an alternative approach, but may induce artifacts also.14 Furthermore, 
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polymers in solutions and gels like mucus are dynamic, which a static SEM image cannot 
show.14,74 Because of this dynamic nature, a non-adhesive particle whose diameter is 
comparable to the average mesh size may be able to percolate through the mucus,74,75 
which might not be evident from SEM image analysis. Particle tracking allowed us to 
overcome these challenges and probe the microstructure of fresh, minimally perturbed 
airway mucus samples. 
To effectively shield against adhesive hydrophobic and electrostatic interactions 
and minimize protein binding, PEG must be densely grafted to the particle surface. PEG 
tends to adopt an extended “brush” conformation if the surface density is sufficiently 
high that the distance between grafted PEG chains is smaller than their Flory radius (the 
unconstrained polymer size in a good solvent).76,77 In contrast, the PEG adopts a 
“mushroom” conformation when PEG density is lower, such that adjacent chains are far 
enough apart to generally avoid overlap. An unconstrained 5 kDa PEG chain has a Flory 
radius of ~6 nm.18 We recently reported that our 100 nm PS-PEG particles with near-
neutral zeta-potential had approximately 0.09 PEG chains per nm2 of particle surface, or 
one chain per ~11 nm2;  this corresponds to ~3.3 nm between the attachment point of 
neighboring PEG chains, which is within the brush regime for 5 kDa PEG.18 Dense PEG 
brush coatings have been shown to better shield nanoparticles against interactions with 
biomolecules.76  
While we found that PEG-coated particles as large as 200 nm in diameter can 
diffuse in respiratory mucus gel, we note that in vivo, the mucus gel layer sits atop the 
periciliary layer (PCL), which is expected to serve as a further barrier to particles.  
Recent evidence suggests that the PCL is not a watery liquid, as previously thought, but 
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rather consists of a dense brush of macromolecules grafted to cilia and the epithelial 
surface.15 In primary human bronchial epithelial (HBE) cell cultures, the periciliary brush 
has a maximum mesh size of approximately 40 nm.15 This may provide an extra layer of 
protection to the airway epithelia, beyond that of the mucus gel studied here, in airway 
regions with an intact PCL. There may be gaps in the PCL above secretory cells,78 so 
particles might be able to more readily breach the lung’s protective barrier at those 
locations. We must also emphasize that in healthy individuals, ciliary beating constantly 
propels mucus out of the lungs, while continuous mucin secretion simultaneously 
replenishes the mucus gel layer.13 To reach the PCL, a nanoparticle must therefore 
diffuse through the mucus gel layer faster than it is swept away by mucociliary activity. 
We recognize that mucus collected by the endotracheal tube method may be 
altered compared to the mucus gel layer in vivo. When the patients were in the operating 
room, their endotracheal tubes were connected to a passive heat and moisture exchanger 
(Humid-Vent) to humidify the ventilated air. Still, the ventilated air may be drier than air 
humidified by passing through the upper respiratory tract during normal respiration. 
Endotracheal tube mucus could thus be dehydrated compared to mucus in vivo.54 If so, 
the work here would set a conservative bound on the nanoparticle size capable of 
penetrating respiratory mucus. However, our rheological and biochemical data suggest 
that the endotracheal tube mucus samples were of good quality. First, in terms of 
rheology, we measured tan(𝛿) = 0.30 at ω = 1 rad/s; this is in close agreement with 
previously published values for respiratory mucus collected by the endotracheal tube 
method (0.33) and by a bronchoscopy brush method (0.28) from individuals with no 
respiratory disease.54,56 Second, in terms of total solids content, we measured an average 
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of 6.9% solids. This is in reasonable agreement with the 5.2% solids reported by 
Matthews et al. for “normal” mucus, which they collected from laryngectomized 
patients.79 Other papers report that normal mucus is 2 to 3% solids, but those values are 
based on mucus collected from HBE cell cultures.15,47 Third, with regards to biochemical 
composition, we measured mucin contents ranging from 8 to 22% of the total solids, 
which is consistent with reports that mucins account for less than 30% of the mucus 
solids.13 We found that DNA was less than 1% of the total solids on average, as expected 
for healthy respiratory mucus, and in contrast to the elevated (approximately10-fold 
higher) DNA concentration in CF sputum, for instance.13,51,79  
Previously, we characterized sputum expectorated by adult CF patients.50 
Comparing that work with the present study, PEG-coated 200 nm particles were slowed 
65-fold in CF sputum and 41-fold in normal airway mucus at a timescale of 1 s, 
compared to their theoretical diffusivities in water. This difference may be due to the 
increased concentrations of DNA, actin, and other debris released by dead inflammatory 
cells in CF sputum.13 In both normal mucus and CF sputum, 500 nm particles were 
immobilized. Although the collection methods are different, making direct comparison 
challenging, this finding implies that both normal and CF mucus are significant barriers 
to nanoparticle transport. We note that in our previous work with CF sputum, 100 nm PS-
PEG particles were immobilized, which we attributed to difficulty coating these smaller, 
more highly curved particles with a dense PEG layer.50 However, we have since 
engineered improved 100 nm particles with denser PEG coatings, as discussed.18,49,53 We 
show here that these improved 100 nm PS-PEG particles can penetrate normal airway 
mucus, and they are also capable of penetrating CF sputum (to be published). Thus, the 
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difference in transport of 100 nm PS-PEG particles between our previous CF paper and 
the present work with normal airway mucus reflects the quality of the PEG coating, not 
the disease state. 
We found that there are profound differences between respiratory mucus and 
mucus collected from the female reproductive tract.49,53 Whereas 500 nm PS-PEG 
particles are immobilized in airway mucus, they can effectively penetrate cervicovaginal 
mucus (CVM) from healthy women. This indicates that the airway mucus collected here 
has a significantly tighter mesh than does CVM. This may reflect the greater need for 
particle trapping in the airways, which are continuously exposed to the external 
environment. Despite its larger mesh spacing, CVM’s bulk viscous and elastic moduli are 
roughly one order of magnitude greater than those of airway mucus.80 This may be 
explained as follows: Mucins in native CVM are bundled by hydrophobic interactions,80 
and may be more bundled than are mucins in airway mucus. Increased mucin bundling in 
CVM would produce thicker mucin fibers, resulting in larger viscoelastic moduli and a 
more porous microstructure, of CVM compared to airway mucus. This finding agrees 
with experiments using a model actin gel, where it was found that for a fixed actin 
concentration, increased actin fiber bundling caused both increased mesh size and 
increased elastic modulus.81 To further understand how mucus differs between different 
anatomical locations, the techniques used here could also be applied to characterize the 
rheology and permeability of mucus from other mucosal tissues, such as the GI tract.  
Another difference we found in this study was that approximately 40% of 100 nm 
PS-COOH particles are mobile in respiratory mucus, whereas 100 nm PS-COOH 
particles are almost entirely immobilized in CVM.49 This suggests that particles with 
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hydrophobic and anionic surface regions, such as PS-COOH particles, may be less 
adhesive to respiratory mucus than they are to CVM. It is possible that abundant 
endogenous surfactants in airway mucus82,83 may coat hydrophobic regions on mucins or 
on the particles, making the PS-COOH particles less adhesive to respiratory mucus. The 
consequences of this phenomenon on particle transport are more noticeable for smaller 
particles, most likely because smaller particles are less likely to form multiple contacts 
with the mucus gel network, and thus are less avidly adhered. One finding supporting this 
explanation is that, compared to untreated CF sputum, 200 nm PS-COOH particles and 
adhesive rod-shaped gene vectors exhibit enhanced transport in sputum treated with N-
acetyl cysteine, which increases the pore size by cleaving disulfide crosslinks in the 
mucin mesh.68,84 The 100 nm PS-COOH particle transport data suggests that viruses and 
very small environmental pollution particles that deposit in the airways may be capable 
of penetrating the airway mucus gel layer to some extent, increasing the threat they pose 
to the body. For instance, our results suggest that the influenza virus (d ≈ 100 nm, smaller 
than the mucus mesh size) should be able to penetrate respiratory mucus, unless it is 
strongly immobilized by adhesive interactions with mucus constituents.  
 
3.5. Conclusion 
Using multiple particle tracking of non-muco-adhesive probes, we determined the 
microstructure of respiratory mucus collected from endotracheal tubes of humans without 
lung disease. We found that PEG-coated particles as large as 200 nm are capable of 
penetrating normal human airway mucus. Whereas respiratory mucus is a viscoelastic 
solid at the bulk level, small PS-PEG particles ≤ 200 nm can penetrate the mucus as if it 
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were primarily a viscous liquid. We also established principles and methods that can be 
applied to design and test novel therapeutic mucus-penetrating nanoparticles for airway 
delivery, as well as to study the transport of respiratory viruses and environmental 





Table 3.1. Particle characterization and transport summary. 
Particle sizea, nm Material Diameterb, nm ζ-potentialc, mV Dw/⟨Deff⟩d αe 
100 PS-COOH 92 ± 3 -50 ± 3 390 0.68 
100 PS-PEG 99 ± 1 -1 ± 1 26 0.88 
200 PS-COOH 188 ± 1 -54 ± 4 1600 0.54 
200 PS-PEG 219 ± 3 -5 ± 1 41 0.82 
500 PS-COOH 508 ± 2 -73 ± 3 980 0.54 
500 PS-PEG 549 ± 6 -3 ± 1 590 0.59 
 
a Provided by the manufacturer. 
b Measured by dynamic light scattering. Error values represent standard deviation of 3 
measurements. 
c Measured in 10 mM NaCl at pH 7.4. Error values represent standard deviation of 3 
measurements. 
d Dw is the diffusivity of particles in water, as calculated from the Stokes–Einstein 
equation. ⟨Deff⟩ is the effective diffusivity of particles in mucus measured at a time scale 
of 1 s, and it is calculated as ⟨Deff⟩ = ⟨MSD(τ)⟩/4τ with τ = 1 s. The ratio Dw/⟨Deff⟩ 
indicates the average factor by which the transport of particles in mucus is slowed 
compared to in water. 
e Calculated by fitting ⟨MSD(τ)⟩ to ⟨MSD(τ)⟩ = kτα for τ between 0.2 and 3.2 s. For 







Figure 3.1. Bulk rheology of airway mucus. 
 (A) Strain-dependent viscous and elastic moduli from 0.2 to 10% strain at a frequency of 
1 Hz (6.28 rad/s). (B) Frequency-dependent viscous and elastic moduli from 0.1 to 100 










Figure 3.2. Scanning electron micrograph shows microstructure of airway mucus. 
Scale bar represents 500 nm. Because the specimen was fixed with glutaraldehyde and 
stained with heavy metals, and furthermore because the image shows multiple layers, the 








Figure 3.3. Representative trajectories of nanoparticles in airway mucus. 
Trajectories show 3 s of motion. The trajectories presented are within one standard error 
of the mean MSD for each particle type.  (A) 100 nm PS-COOH particles. (B) 100 nm 
PS-PEG particles. (C) 200 nm PS-COOH particles. (D) 200 nm PS-PEG particles. (E) 








Figure 3.4. Ensemble-averaged geometric mean squared displacement (⟨MSD⟩) as a 
function of timescale for nanoparticles in airway mucus. 
 (A) 100, 200, and 500 nm PS-PEG particles. (B) 100, 200, and 500 nm PS-COOH 
particles. Data represents 5 mucus samples, with at least 100 particles of each particle 
type tracked per sample. Error bars are presented as standard error of the mean. For 
reference, blue line in (B) denotes the MSD of 100 nm particles in water, calculated using 






Figure 3.5. Distribution of individual particle mean squared displacements at a time 
scale of 3 s. 
Data represents 5 mucus samples, with at least 100 particles of each type tracked per 
sample. (A) 100 nm PS-COOH particles. (B) 100 nm PS-PEG particles. (C) 200 nm PS-
COOH particles. (D) 200 nm PS-PEG particles. (E) 500 nm PS-COOH particles. (F) 500 
nm PS-PEG particles. The dashed vertical black lines indicate the threshold for immobile 





Figure 3.6. Micro- vs. macroscopic viscosity of human respiratory mucus. 
Viscosity reported is |η(ω)*|, the magnitude of the complex viscosity, at ω = 1 rad/s. 
Complex viscosity incorporates both the viscous and elastic contributions to a material’s 
rheological behavior. Microscopic viscosity experienced by 100, 200, and 500 nm PS-
PEG probes in respiratory mucus was measured by particle tracking microrheology 
(PTM). Macroscopic viscosity, also called bulk viscosity (dashed horizontal line), was 
measured using a cone-and-plate rheometer. Mucus interstitial fluid (dotted line) was 
characterized by centrifuging mucus samples and measuring the supernatant’s viscosity 
by PTM. For reference, the viscosity of water at 20 °C is also shown (solid horizontal 
line). Viscosity values represent n = 5 mucus samples, and error bars indicate standard 
error of the mean. Brackets with asterisks denote statistically significant differences (*, P 





4. OVERCOMING THE CYSTIC FIBROSIS SPUTUM BARRIER TO LEADING 
ADENO-ASSOCIATED VIRUS GENE THERAPY VECTORS2 
 
4.1. Introduction 
Cystic fibrosis (CF) is an autosomal recessive disorder that afflicts approximately 
70,000 people worldwide.3 In patients with CF, absence of functional cystic fibrosis 
transmembrane conductance regulator (CFTR), a chloride channel, impairs salt and water 
balance at epithelial surfaces.6 Lung disease is the primary cause of morbidity and 
mortality in CF. A vicious cycle of airway obstruction, chronic infection, and 
inflammation causes progressive decline in lung function.6,8 The median predicted 
survival age of CF patients has climbed in recent decades, but it is still only about 40 
years.6 Advances in recent decades include aerosolized antibiotics, pancreatic enzyme 
supplements, and improved devices and medications to help clear secretions from the 
lungs. 
Following discovery of the CFTR gene in 1989, researchers envisioned treating 
CF by delivering the correct gene directly to patient lungs to restore CFTR function.8 In 
cell culture and animal models, gene therapy has successfully mediated CFTR expression 
and corrected chloride current.85,86 However, achieving clinical efficacy in humans has 
proven challenging.8,87 Despite 25 clinical trials testing adenovirus (AdV), adeno-
associated virus (AAV), and non-viral vectors, gene therapy has yet to produce clinically 
significant improvements in CF patient lung function.8,87 These disappointing results 
have been blamed on immune response to the gene vectors, inefficient transduction of 
                                                 
2 This chapter appears in Schuster, BS, Kim, AJ, Kays, JC, Kanzawa, MM, Guggino, WB, Boyle, MP, Muzyczka, N, Suk, JS and 
Hanes, J. Overcoming the Cystic Fibrosis Sputum Barrier to Leading Adeno-associated Virus Gene Therapy Vectors. Molecular 
Therapy. 2014; 22(8):1484-93 
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human airway epithelium via the apical membrane, and weak promoters to drive gene 
expression.8 
Another major obstacle to pulmonary gene therapy for CF is the layer of 
viscoelastic airway secretions that coats the CF lung epithelium.8,88,89 CF airway 
secretions are a gel comprised of entangled and cross-linked mucins, DNA, actin, and 
other macromolecules and cell debris.13 This biopolymer network may trap inhaled 
particles by steric obstruction and specific or non-specific adhesive interactions.17,89 
Nevertheless, most CF gene therapy preclinical research has been conducted using cell 
culture and animal models that lack CF-like airway secretions and thus do not fully 
mimic the CF lung.8 We previously found, in a proof-of-concept study, that sputum from 
five CF patients strongly hindered diffusion of AdV and AAV serotype 5 (AAV5).90 
Likewise, CF sputum inhibited AdV-mediated transfection in in vitro and ex vivo 
experiments.91 These studies underscore that airway secretions can act as a barrier and 
prevent inhaled viral vectors from reaching target lung cells.  
Given its clinical significance, much remains to be learned about the CF sputum 
barrier to AAV gene therapy. AAV2 was the first AAV serotype characterized and the 
only one tested in CF clinical trials, yet whether AAV2 can penetrate CF sputum is 
unknown. AAV is a leading viral gene delivery platform, and numerous other AAV 
serotypes have been investigated for their ability to transduce airway cells.88,92 AAV5 
exhibited enhanced transduction efficiency in the mouse lung compared to AAV2,92 
which motivated our prior work testing AAV5 diffusion in CF sputum.90 A more recent 
study showed AAV1 outperformed AAV5 in human primary airway cells and in 
chimpanzees.88 Because AAV1 has emerged as a promising candidate for future CF gene 
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therapy clinical trials, its ability to penetrate CF sputum must also be assessed. All AAV 
serotypes have non-enveloped, icosahedral, ~25 nm diameter capsids,93 so the sputum 
mesh will sterically obstruct all serotypes equally. However, the serotypes differ in their 
tropisms and binding affinities,9,93-95 which may alter their adhesion to, and thus their 
diffusion through, sputum.  
Here, we investigated diffusion of AAV1 and AAV2, compared to AAV5, in 
sputum samples from adult CF patients. Using multiple particle tracking and automated 
image analysis, we measured the movement of >30,000 AAV particles at single virus 
resolution in >20 patient samples. We observed that CF sputum hindered a large fraction 
of AAV particles, regardless of serotype. The sizeable patient population and number of 
viruses studied enabled us to examine inter- and intra- patient variability. Furthermore, 
we demonstrated two methods to improve AAV diffusion in CF sputum: virus capsid 
modification and mucolytic therapy with N-acetylcysteine. Our findings suggest 
strategies and future research directions for overcoming the CF sputum barrier to 
clinically successful inhaled gene delivery. 
 
4.2. Materials and methods 
4.2.1. Production of AAV 
Recombinant AAV was prepared by the Vector Core at the University of Florida 
Powell Gene Therapy Center. AAV1, 2, and 5 were packaged with pTR-UF11 (single-
stranded enhanced green fluorescent protein [eGFP] genome). For AAV1, the rep2, cap1, 
and AdV early genes were contained in the helper plasmid pKrap1A. For AAV2, the 
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rep2, cap2, and AdV genes were contained in the helper plasmid pDG-KanR. For AAV5, 
the rep2, cap5, and AdV genes were contained in the helper plasmid pXYZ5.  
The mutant AAV2 studied in this paper had the arginine residues at capsid 
positions 585 and 588 mutated to alanines. These mutations have previously been shown 
to reduce heparin binding.93,96,97 The virus packaged pds-eGFP (double-stranded eGFP 
genome). The helper plasmids were pXX6 (containing the AdV genes) and mutant 
pIM45 (containing rep2 and the mutant cap2).  
AAV was produced as previously described.98,99 Briefly, the vectors were 
produced via calcium phosphate-based co-transfection (for AAV1, 2, and 5) or triple 
transfection (for the AAV2 mutant) of plasmid into HEK293 cells. The transfected cells 
were incubated for approximately 72 hours, then harvested and lysed by freeze/thaw. The 
resultant cell lysates were digested with Benzonase, centrifuged to remove cellular 
debris, and purified by iodixanol density step gradient centrifugation followed by ion 
exchange chromatography. Buffer exchange and concentration were performed using 
centrifugal concentrators into the final stock buffer (PBS).  
AAV produced by this technique is at least 99% pure, as determined by 
PAGE/silver stain.100 The iodixanol density gradient centrifugation procedure separates 
full, genome-containing capsids from both free capsid proteins and empty capsids.98 This 
was confirmed by comparing the capsid ELISA titer (PROGEN Biotechnik GmbH, 
Heidelberg Germany), using monoclonal antibodies that recognize only intact capsids, 




4.2.2. Fluorescent labeling of AAV 
For virus tracking, AAV was labeled with the amine-reactive fluorescent dye 
Alexa Fluor 647 carboxylic acid, succinimidyl ester (AF647; Life Technologies, 
Carlsbad, CA). The autofluorescence of CF sputum is minimized at long-wavelength 
excitation, so using a deep red fluorophore such as AF647 allowed us to more easily 
distinguish the AAV particles. The labeling protocol was based on methods reported in 
the AAV literature.101 AF647 was reconstituted in DMSO and added, along with borate 
buffer (pH 8.3), to AAV. The final reaction volume was 150 µL and contained 
approximately 1011 virus particles, 15% (v/v) DMSO, 100 mM borate buffer, and 100 
µM AF647. The reaction was placed on a lab rotator at 4 °C in the dark. After two hours, 
unreacted dye molecules were removed by buffer exchange into PBS using a standard 
separation technique, gel filtration chromatography,101 whereby unreacted dye was 
retained in the gel filtration media while labeled virus eluted from the column. The gel 
filtration media we used was Sephadex G-50 (illustra ProbeQuant G-50 Micro Columns; 
GE Healthcare, Little Chalfont, UK). Labeled virus was stored in 5 µL aliquots at -80 °C. 
 
4.2.3. Quantitative real-time PCR 
Titers of AAV and AF647-labeled AAV were measured using quantitative real-
time PCR on a MyiQ2 thermal cycler (Bio-Rad, Hercules, CA) using SsoAdvanced 
SYBR Green Supermix (Bio-Rad). Primers against the CMV/chicken beta actin promoter 
in the AAV genomes were purchased from Eurofins MWG Operon (Huntsville, AL) with 
the following sequences: forward primer, 5’-TCCCATAGTAACGCCAATAGG-3’, 
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reverse primer, 5’-CTTGGCATATGATACACTTGATG-3’.99 Equal numbers of viruses 
were then used to compare the infectivity of AAV2 and AAV2-AF647 in cell culture. 
 
4.2.4. Cell transduction experiments and flow cytometry  
AAV transduction experiments were conducted using a human bronchial 
epithelial cell line, BEAS-2B. The cells were grown in DMEM/F12 (Life Technologies) 
supplemented with 10% fetal bovine serum (Life Technologies) and antibiotics (100 
U/mL penicillin and 100 µg/mL streptomycin; Quality Biological, Gaithersburg, MD). 
Cells were incubated at 37°C in a 5% CO2 atmosphere. For the transduction experiments, 
cells were seeded at a density of 40,000 cells/well in 24-well plates. After seeding, cells 
were allowed to grow for 24 h before adding AAV.  
For comparing the infectivity of AAV2 with AF647-labeled AAV2, virus was 
added to the cells at a multiplicity of infection (MOI) of 2 × 103 vgc/cell. GFP expression 
was measured by flow cytometry 48 h after adding the virus.  
We conducted heparin competition experiments to check the relative heparin 
binding strengths of AAV2 and the AAV2 mutant. In these studies, prior to the addition 
of virus, the regular media was replaced with media into which had been dissolved 
heparin sodium salt (from porcine intestinal mucosa; Sigma-Aldrich, St. Louis, MO) at 
concentrations of 10, 25, or 100 µg/mL. An MOI of 105 vgc/cell was used throughout, to 
achieve significant GFP expression for all serotypes, including the AAV2 mutant, which 
generally has lower transduction efficiency than wild-type AAV2 in vitro.93 The media 
was removed 3 h after adding the virus and replaced with fresh media without heparin. 
GFP expression was measured by flow cytometry 48 h after adding the virus.  
64 
 
To determine if NAC affected AAV1 transduction, we conducted experiments in 
which, immediately prior to adding virus, the regular cell culture media was replaced by 
media containing NAC at a concentration of 5 mM. AAV1 was then added at an MOI of 
2 × 104 vgc/cell. GFP expression was measured by flow cytometry 48 h after adding the 
virus.   
Flow cytometry was conducted with an Accuri C6 flow cytometer (BD 
Biosciences, San Jose, CA) using the 488 nm laser. GFP fluorescence was detected in the 
FL1 channel with a 533/30 nm band-pass filter. For each well on a 24-well plate, 10,000 
cells were counted.  
 
4.2.5. CF sputum sample collection 
Expectorated sputum samples were collected from patients at the adult CF clinics 
at Johns Hopkins (n = 23) and the University of Alabama at Birmingham (n = 3). 
Samples from Hopkins were stored at 4 °C and analyzed the day after collection. Samples 
from Alabama were shipped overnight, on ice, to Hopkins and also analyzed the day after 
sample collection. Samples were collected under written informed consent, in accordance 
with Institutional Review Board approval and following Declaration of Helsinki 
protocols.  
Patients involved in this study received no mucolytics other than Pulmozyme® 
(rhDNase, which cleaves DNA in sputum) as part of their treatment regimen. 19% of 
patients received Pulmozyme® between 2 and 6 hours prior to when their sputum sample 
was collected, 50% of patients last received Pulmozyme® the day before sample 




4.2.6. Preparing PS-PEG and PS-PEG-AF647 nanoparticles 
PEG-coated polystyrene particles (PS-PEG) were prepared as detailed 
previously.17 Briefly, fluorescent carboxylate-modified polystyrene spheres (PS-COOH), 
100 nm and 500 nm in diameter, were purchased from Molecular Probes or Bangs Labs. 
To coat the PS-COOH particles with PEG, 5 kDa methoxy-PEG-amine (Creative 
PEGWorks, Winston-Salem, NC) was covalently coupled to carboxyl groups on the PS-
COOH particles using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS; Sigma-Aldrich) in 
borate buffer (pH 8.3). After reacting for 4 h, the resulting PS-PEG particles were 
centrifuged and washed in ultrapure water. Our lab recently measured the surface density 
of PEG on PS-PEG particles prepared according to this protocol to be 0.09 PEG/nm2, 
which suggests the PEG layer has a dense brush conformation ideal for resisting protein 
adhesion.18 We did not use AAV-sized polymeric particles in this paper because 
commercially available 20 nm PS-COOH particles are more challenging to PEGylate 
sufficiently to block adhesion to mucus, probably due to the small radius of curvature, 
and they also have lower fluorescence intensity and consequently are more difficult to 
track, compared to 100 nm or larger PS-COOH particles. 
To prepare 100 nm PS-PEG particles labeled with AF647 (PS-PEG-AF647), a 
modified version of this protocol was used. First, the carboxyl groups on the PS-COOH 
particles were activated by reacting PS-COOH particles, NHS, and EDC in 50 mM MES 
buffer (pH 6.0) for 1 h. Next, the particles were centrifuged and resuspended in 100 mM 
borate buffer (pH 8.3), to which 5 kDa carboxyl-PEG-amine (JenKem Technology USA, 
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Allen, TX) was added at a 5-fold molar excess to the number of carboxyl groups on the 
PS-COOH particles. This mixture was allowed to react for 2 h, to couple the amine 
groups on the PEG with the activated carboxyl groups on the particles. Then, the particles 
were centrifuged and resuspended in fresh borate buffer, to which was added NHS, EDC, 
and Alexa Fluor 647 cadaverine, disodium salt (Life Technologies). The dye was added 
at a 1:1 molar ratio to the number of carboxyl groups on the PS-COOH particles (the 
maximum number of PEG chains that could have attached). This mixture reacted 
overnight, coupling the amine on the AF647-cadaverine with the carboxyl group on the 
free end of the PEG chains. Finally, the PS-PEG-AF647 particles were centrifuged and 
washed in ultrapure water until the supernatant was free of visible dye. 
PS-COOH, PS-PEG, and PS-PEG-AF647 particles were stored at 4 °C. For 
particle tracking experiments, the particles were diluted with ultrapure water to 
concentrations ideal for tracking individual particles.  
 
4.2.7. Particle size measurements 
 AAV and nanoparticle size were measured by dynamic light scattering using a 
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK), which uses a 633 nm laser and 
has a 173° scattering angle. Measurements were conducted at 25 °C. AAV was 
suspended in PBS (pH 7.4), while the nanoparticles were suspended in PBS diluted to 




4.2.8. Scanning electron microscopy  
Sputum was prepared for electron microscopy following an established protocol, 
as described previously.17 Briefly, sputum samples were fixed in 2% glutaraldehyde, 
postfixed in 1% OsO4, and then stained with 2% uranyl acetate. The specimens were then 
dehydrated through a graded series of ethanol solutions, followed by immersion in 
hexamethyldisilazane, and then desiccated under vacuum overnight. The samples were 
attached to aluminum stub mounts, sputter coated with 20 nm of AuPd, and imaged with 
a field-emission scanning electron microscope (LEO 1530 FESEM; Zeiss, Jena, 
Germany). 
 
4.2.9. Particle tracking: sample preparation and microscopy 
Movement of viruses and nanoparticles in sputum was measured by multiple 
particle tracking. The sample preparation procedure was designed to minimize 
manipulation of the sputum and maintain its microarchitecture. Sputum aliquots (~30 µL 
each) were withdrawn from the sputum sample using a Wiretrol (Drummond Scientific 
Company, Broomall, PA) and dispensed into custom microscopy chambers. Aliquots 
were withdrawn from the same approximate location in the sputum sample to minimize 
the effects of intra-sample heterogeneity.  
To each sputum aliquot was added 0.5 µL of one serotype of AF647-labeled 
AAV, plus polymeric nanoparticles as controls: either 0.5 µL of green fluorescent 500 
nm PS-PEG particles, 0.5 µL of red fluorescent 100 nm PS-PEG particles, or 0.5 µL each 
of the 100 nm and 500 nm PS-PEG particles. Thus, in total, no more than 1.5 µL of virus 
and nanoparticle suspensions were added to ~30 µL of sputum, so the sputum aliquots 
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were diluted 5% v/v or less. In our current and previously published work, we found that 
dilutions of this magnitude did not alter the ability of sputum to sterically and adhesively 
trap particles.50,84  
After adding the particles, the sputum aliquots were gently stirred with a pipette 
tip, and then the chambers were sealed with a coverslip to prevent sample dehydration. 
After incubating the chambers for 1 h, they were imaged at room temperature using an 
inverted epifluorescence microscope (Axio Observer; Zeiss) located on a vibration 
isolation table and employing a 100x/1.46 NA oil-immersion objective. Care was taken to 
focus the objective at least 2 µm above the coverslip surface to minimize edge effects. 
Movies of virus and nanoparticle motion in the sputum samples were recorded at a frame 
rate of 15 Hz, for 150 or 300 frames, using an EM-CCD camera (Evolve 512; 
Photometrics, Tuscon, AZ). For each sputum sample, five to ten movies of each virus 
serotype or nanoparticle type were collected.  
To determine the effect of the mucolytic drug NAC on AAV transport in CF 
sputum, a solution of NAC (neutralized to a pH of 7) was mixed into sputum to a final 
concentration of 5 mM. For the untreated control, a comparable volume of PBS was 
added to sputum. NAC-treated and control samples were then incubated at 37°C for 30 
min.  AAV1-AF647 was then added to the samples in custom microscopy chambers, the 
slides were incubated for 1 h at 37°C, and imaging was performed using the procedure 
above. In this experiment, the sputum samples were again diluted 5% (v/v) or less. 
Finally, to determine the effect of AF647 labeling on particle transport, we prepared 





4.2.10. Particle tracking analysis 
Movies were analyzed using automated particle tracking software custom-written 
in MATLAB (MathWorks, Natick, MA), based on the algorithm of Crocker and Grier,2 
to determine the x and y positions of particles over time. Images were first processed by 
convolving them with a spatial bandpass filter to reduce noise and non-uniform 
background. Local maxima of pixel intensity were identified as candidate particle 
positions. These positions were refined by calculating the intensity-weighted centroid of 
the bright spots, to yield sub-pixel resolution. By examining particle brightness, size, and 
eccentricity, true particles were retained and spurious ones (noise) discarded. Trajectories 
were constructed by linking particle positions identified in subsequent frames via a 
nearest neighbor method. The time-averaged mean squared displacement (MSD) of each 
trajectory was calculated as MSD(τ) = ⟨[x(t + τ) - x(t)]2⟩ + ⟨[y(t + τ) - y(t)]2⟩ , where τ is 
the time scale, and the angled brackets denote the average over many starting times t. 
Scanning electron microscopy (Figure 4.6) suggests that sputum is isotropic, so the 2-
dimensional MSD measured here equals two-thirds of the three-dimensional MSD. We 
presented our results at a time scale of 1 s; trajectories shorter than 1 s are not useful in 
this context and were thus discarded. There is a possibility that we discarded some rapid 
particles that were in focus for less than 1 s, but our visual observations suggest that is an 
infrequent occurrence. 
Tracking resolution was estimated based on a published method.38 First, the 
signal-to-noise ratio (SNR) was calculated from the experimental movies (particle 
tracking movies of AAV and nanoparticles in sputum). These were compared to a 
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standard curve of static error as a function of SNR, to estimate the static error in the 
experimental movies. The standard curve was generated by affixing particles to a glass 
slide and tracking them under different illumination intensities; the apparent motion of 
these fixed particles is due to static error. For 100 nm PS-PEG particles in sputum, the 
tracking resolution was approximately 25 nm. For AAV, the tracking resolution was 
approximately 75 nm, since the viruses are dim and their positions cannot be estimated as 
accurately. The MSDs of fast particles and viruses – those of greatest clinical interest, 
because they are most likely to penetrate CF sputum – are well above the noise floor at a 
times scale of 1 s.  
 
4.2.11. Statistical analysis 
Student’s t-tests and ANOVA were conducted in MATLAB (MathWorks). Linear 
mixed effects models were constructed using the lme4 package102 in the statistical 
language R to examine the relationship between AAV2 capsid and MSD (at a time scale 
of 1 s) in sputum. In these models, MSD was the dependent variable, and AAV2 capsid 
(mutated or wild-type) was set as a fixed effect. The random effects were patient sample 
number, as well as by-patient random slopes for the effect of AAV capsid. Residual plots 
did not show major deviations from homoscedasticity or normality. The p value was 
calculated by a likelihood ratio test of the full model, which includes AAV capsid type, 
against the null model, which excludes AAV capsid type. Linear mixed-effects models 
were also used to compare the extent of intra- and inter- sample variability; here, MSD of 
100 nm PS-PEG particles was the dependent variable, and both patient and sputum 






4.3.1. Characterization of fluorescently labeled AAV 
We labeled the AAV capsid with a deep red fluorescent dye, Alexa Fluor 647 
(AF647), to track the movement of AAV in freshly collected human CF sputum. To 
assess whether attaching this exogenous dye molecule would affect our subsequent 
studies, we examined the consequences of dye labeling on AAV infectivity and on 
particle transport in CF sputum. 
First, we examined whether AF647 labeling altered AAV infectivity. We infected 
BEAS-2B bronchial epithelial cells with AAV2 or with AF647-labeled AAV2 (AAV2-
AF647) at the same MOI. The virus carried a GFP reporter gene, which allowed us to 
assess transduction efficiency by fluorescence microscopy and flow cytometry (Figure 
4.1a-d). We found no statistically significant difference in gene expression by the cells 
infected with AAV2 as compared to with AAV2-AF647 (two-sided t-test, p = 0.25). 
Next, we examined whether attaching AF647 affected particle diffusion in CF sputum. 
Since we could not image unlabeled AAV, we addressed this question using polystyrene 
(PS) nanoparticles internally labeled with a fluorescent dye, and which were densely 
coated with polyethylene glycol (PEG) to minimize adhesion to sputum (PS-PEG).17,50,103 
We measured the transport in CF sputum of 100 nm PS-PEG particles as compared to 
100 nm PS-PEG particles further labeled with AF647 on the particle surface (PS-PEG-
AF647). A histogram of the mean squared displacement (MSD) of PS-PEG particles in 
CF sputum (Figure 4.1e) was nearly identical to that of PS-PEG-AF647 (Figure 4.1f). 
72 
 
Finally, using dynamic light scattering, we confirmed that dye labeling did not affect the 
size of AAV or PS-PEG particles (Table 4.1). Together, these studies strongly suggest 
that labeling AAV with dye did not alter its biological activity or diffusivity. 
 
4.3.2. Transport of AAV serotypes 1, 2, and 5 in CF sputum 
We studied the diffusion of AAV serotypes 1, 2, and 5, as well as polymeric 
nanoparticles for comparison, in 10 CF sputum samples. Using particle tracking and 
automated image analysis, we analyzed the trajectories of tens of thousands of viruses 
and nanoparticles. Histograms of individual particle MSDs at a time scale of 1 s, 
averaged over the 10 patient samples with each sample equally weighted, are shown in 
Figure 4.2 and Figure 4.7. In 20 ºC water, a 25 nm diameter AAV particle would have a 
two-dimensional MSD of 69 µm2 at 1 s, according to Stokes-Einstein theory.2,39 In 
comparison, all three AAV serotypes were greatly slowed in CF sputum (Figure 4.2b-d). 
Approximately 50% of the AAV particles moved less than 1/1,000th their theoretical 
MSD in water, with MSD < 0.069 µm2 (or log10MSD < -1.2) at 1 s.  
We found that transport rates of individual particles in sputum ranged as much as 
five orders of magnitude (Figures 4.2 and 4.3), compared to approximately three orders 
of magnitude for AAV in water (Figure 4.8), which reflects the heterogeneous nature of 
CF sputum.104 Fast-moving particles are of particular interest, since they have the greatest 
likelihood of penetrating the sputum layer. All AAV serotypes tested had a subpopulation 
of fast-moving particles, which we define as those with MSD ≥ 1 µm2 (or log10MSD ≥ 0) 
at 1 s. Using this definition for fast-moving particles, 15%, 8%, and 6% of AAV1, 
AAV2, and AAV5, respectively, diffused rapidly in CF sputum (Figure 4.2b-d). The 
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MSDs of these fast particles typically increased linearly with time, so if we extrapolate, a 
freely diffusing particle that has an MSD (measured by two-dimensional particle 
tracking) of 1 µm2 at 1 s could penetrate a 10 µm sputum layer (considering only motion 
in the z-direction) in 200 s. Likewise, the same particle could penetrate a 40 µm sputum 
layer in about 50 min. In other words, the small but important subpopulation of fast-
moving particles would be able to traverse physiologically relevant distances13 in under 
an hour, and may be more likely to penetrate the airway secretions and reach epithelial 
cells in vivo prior to being removed by mucociliary clearance. Measurements of 
mucociliary clearance rates in CF patients vary widely; the percentage of inhaled 
particles cleared from CF lungs within an hour ranged from about 15 to 60% in various 
studies.105  
Overall, only approximately 5-15% of AAV particles were diffusive, while the 
majority of particles were greatly hindered or immobilized in sputum. For comparison, 
we also measured the diffusion of polymeric nanoparticles in sputum. Our lab has 
previously shown that small polymeric nanoparticles, if densely coated with PEG to 
render their surfaces hydrophilic and resistant to mucus adhesion, diffuse faster in sputum 
than do comparably sized adhesive particles. However, particles larger than the mesh size 
of the sputum, even if PEG-coated, are sterically immobilized.17,50 Here, we found that in 
contrast to AAV, nearly 40% of the adhesion-resistant 100 nm PS-PEG particles diffused 
rapidly (Figure 4.2a). Meanwhile, only 3% of the 100 nm uncoated carboxylate 
polystyrene particles (PS-COOH), and only 1% of the 500 nm PS-PEG particles, diffused 




4.3.3. Patient-to-patient variation in AAV transport 
We found that AAV and 100 nm PS-PEG particle mobility varied substantially 
from patient to patient. Figure 4.3a shows boxplots of particle MSDs (at a time scale of 1 
s) for sputum samples from 10 CF patients; Figure 3b shows representative trajectories of 
particles in three of those samples. On one end of the spectrum is patient 1, in whose 
sputum sample the majority of AAV and 100 nm PS-PEG particles were immobilized, as 
illustrated by their highly constrained trajectories. Towards the other end of the spectrum 
is patient 9, in whose sputum sample larger fractions of AAV and 100 nm PS-PEG 
particles were diffusive, as can be seen from their Brownian trajectories (Figure 3b). 
Particle transport in sample 1 was significantly different from that in sample 9 (and also 
significantly different from that in samples 4, 8, and 10; p < 0.01 by two-way ANOVA 
followed by Tukey’s HSD test). The three AAV serotypes tested had similar transport 
rates within most of the samples. However, in patients 5 and 7, different serotypes 
exhibited divergent transport behavior. Those sputum samples may have had different 
binding affinities for different AAV serotypes, but intra-sample variability likely also 
contributed to the variation.  
To assess the extent of inter- vs. intra- sample variability, we tracked 100 nm PS-
PEG particles in the same sputum aliquots in which we tracked the various AAV 
serotypes. This provided us with transport data of one particle type in multiple sputum 
aliquots from each of nine CF sputum samples (Figure 4.9). From this 100 nm PS-PEG 
particle transport data, we found that the variance between samples of log10MSD was 
1.00, which was 50 times the variance within samples, 0.02 (linear mixed-effects 
model102 fit by maximum likelihood). This strongly suggests that the variation among 
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different samples can largely be attributed to patient-to-patient differences, rather than to 
intra-sputum sample heterogeneity. 
We investigated whether patients’ pulmonary function test results (summarized in 
Table 2; higher scores indicate better lung health) could explain the patient-to-patient 
variation in AAV transport, but we did not find strong correlations. For instance, we 
found that median log10MSD at 1 s of AAV2 increased marginally with forced expiratory 
volume (R2 = 0.33) and forced vital capacity (R2 = 0.12). Similarly, we found only weak 
correlations between AAV transport rates and the measured solids content (percent dry 
weight17) of sputum samples (e.g., R2 = 0.105 for AAV2).  
Finally, we note that patients involved in this study received no mucolytics other 
than Pulmozyme®. Furthermore, particle transport was not faster in sputum from patients 
who received Pulmozyme® between 2 and 6 hours prior to when their sputum sample 
was collected (patients 2 and 5 in Figure 4.3), as compared to those who last took 
Pulmozyme® the day before sample collection (patients 1, 3, 7, and 9), and as compared 
to those not on Pulmozyme® (patients 4, 6, 8 and 10 in Figure 4.3). This agrees with our 
prior finding that Pulmozyme® treatment of sputum ex vivo did not affect particle 
transport.68,84 Thus, Pulmozyme® treatment status does not appear to be responsible for 
the patient-to-patient variation in particle transport observed here. 
 
4.3.4. Effect of AAV2 capsid mutation 
Adhesion can immobilize particles in sputum, so we next investigated whether 
modifying the viral capsid to reduce adhesion could improve AAV transport. AAV2 
binds to heparan sulfate proteoglycan and heparin.93 This may pose a challenge for 
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sputum penetration because heparan sulfate is abundant in human tissues and elevated in 
the CF lung,106 and has also been identified in sputum from patients with 
bronchiectasis,107 a key feature of CF.6 Thus, we hypothesized that a mutant AAV2, 
whose capsid was mutated at positions 585 and 588 to reduce heparin binding, as 
previously described,93,96,97 would diffuse faster than AAV2 in sputum. 
First, to confirm that the AAV2 mutant indeed had reduced binding affinity for 
heparin, we conducted an in vitro heparin competition assay (Figure 4.4a). We added 
AAV2 or the AAV2 mutant to BEAS-2B bronchial epithelial cells bathed in media with 
increasing concentrations of dissolved heparin. We assessed transduction efficiency by 
measuring AAV-mediated GFP expression using flow cytometry. Indeed, heparin 
inhibited AAV2 transduction significantly more strongly than it inhibited the AAV2 
mutant (t-test; p < 0.01) for each of the three heparin concentrations tested. To check the 
validity of our assay, we confirmed that heparin did not inhibit BEAS-2B transduction by 
AAV1 or AAV5, as expected (Figure 4.10).  
To study the effect of the capsid mutation on diffusion in sputum, we tracked 
AAV2 and the AAV2 mutant in sputum samples from 17 patients (Figure 4.4b). We 
found that the capsid mutation did affect AAV transport (χ2 = 6.86, p = 0.0088), 
increasing the median MSD at a time scale of 1 s by a factor of 2.2 ± 1.3. In four of the 
sputum samples, the median MSD of the AAV2 mutant was more than five times that of 
AAV2. Furthermore, in two sputum samples, there was more than an order of magnitude 
increase. However, since steric obstruction and adhesion to other sputum components 
besides heparan can also contribute to hindering AAV motion, we did not observe the 
largest improvements specifically in samples where AAV2 diffusion was poor. Overall, 
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the data suggest that engineering the AAV2 capsid to reduce its adhesion to heparin can 
improve AAV2 transport in sputum.  
 
4.3.5. Effect of N-acetylcysteine treatment 
 Previously, our group reported that pretreatment of CF sputum with the mucolytic 
drug N-acetylcysteine (NAC) resulted in improved transport of PS-PEG particles and 
non-viral gene carriers through the sputum.68,84 NAC, which is FDA-approved for various 
routes of administration, including inhalation, breaks disulfide bonds that crosslink 
mucins into polymers and thereby reduces sputum viscoelasticity.13,89 Here, we 
investigated whether pretreatment of sputum with NAC would also enhance AAV 
diffusion.  
 We measured AAV1 diffusion in untreated CF sputum compared to sputum 
pretreated with 5 mM NAC. We chose this concentration based on our earlier finding that 
millimolar concentrations of NAC enhanced PS-PEG particle transport in sputum, 
whereas concentrations one order of magnitude lower were much less effective.68 NAC 
solution prescribed for inhalation (Mucomyst®) contains a concentration of 1.2 M, or 
20%, NAC. Following a single treatment of NAC delivered by an LC Star jet nebulizer, 
the NAC concentration in the upper airways (generations 1-10) can reach a maximum 
concentration of about 50 mM, with the concentration exceeding 10 mM for more than 1 
hour. Lower doses are achieved in the small airways (C. Ehre, personal communication, 
2014). We found that 5 mM NAC can have a large effect on AAV1 transport (Figure 
5a,b; we note that the sputum samples used in the NAC study were different from the 
samples used in Figures 4.2 and 4.3, and thus the percentage of fast AAV1 particles 
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differs between Figures 4.2b and 4.5a). On average, more than 47% of the AAV1 
particles diffused rapidly in NAC-treated sputum, compared to only 5% in untreated 
sputum. Again, we observed substantial sample-to-sample variation. In three of the five 
sputum samples tested, NAC improved AAV transport by one order of magnitude, 
whereas in two samples, NAC had little effect.  
 For NAC to be viable as an adjuvant for CF gene therapy, AAV must maintain its 
ability to transduce airway epithelial cells in the presence of NAC. We therefore assessed 
AAV1 transduction of BEAS-2B cells with and without 5 mM NAC in the cell culture 
media (Figure 4.5c). We found that NAC only slightly reduced transduction (by 10%; 
one-sided t-test, p = 0.027). Together, our experiments indicate that NAC can increase 
AAV1 penetration through sputum at concentrations that do not dramatically affect the 
virus’s ability to transduce cells in culture. We expect similar results for other AAV 
serotypes, as NAC works in a non-specific manner by disrupting mucin crosslinking. 
 
4.4. Discussion 
Here, we report that CF sputum strongly hindered the transport of clinically and 
preclinically tested AAV serotypes, including AAV1, 2, and 5. We estimate that only 5-
15% of AAV particles can penetrate a physiologically relevant distance in sputum fast 
enough to avoid clearance. This finding suggests that the CF sputum barrier likely 
contributed to the disappointing results of AAV2 clinical trials, by preventing most of the 
inhaled gene vectors from reaching airway epithelial cells. The inability of AAV to 
rapidly penetrate sputum necessitates strategies to overcome this barrier. We discovered 
that modulating the adhesive interactions and steric obstruction of AAV in sputum could 
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improve virus transport, which suggests that it may be possible to overcome the CF 
sputum barrier to AAV gene therapy. Our discoveries were enabled by using multiple 
particle tracking and automated image analysis to examine tens of thousands of virus 
particles in >20 patient samples. 
Adhesion is likely the primary mechanism by which sputum hinders AAV 
diffusion. There was a substantially smaller fraction of fast-moving AAV than of 100 nm 
PS-PEG particles – even though AAV is approximately four times smaller in diameter 
(~25 nm). This most likely occurred because AAV adheres to the network of 
biomolecules present in sputum, whereas the PEG-coated particles resist adhesion 
because of their adhesion-resistant surfaces.17,50 Viruses may bind to sputum components 
non-specifically, such as by electrostatic interactions.108 AAV may also adhere to sputum 
by specific binding interactions. AAV2 binds specifically to heparan sulfate 
proteoglycan,93 which is abundant in the CF lung.106 AAV5 binds to α2,3 N-linked sialic 
acids,94 while AAV1 binds to both α2,3 and α2,6 N-linked sialic acids.95 Mucins are rich 
in sialic acids, though predominantly of the O-linked variety.95 One study demonstrated 
that AAV5 did bind to purified mucin,109 though other studies showed that AAV1 and 
AAV5 did not bind strongly to purified mucin.95,110 Mucins from different sources and 
disease states may vary in their glycosylation, and this could explain the contradictory 
reports. Secondary receptors have also been identified for AAV2 and AAV5.9 Finally, 
antibodies may trap AAV in sputum.89 Because of their small size, antibodies diffuse 
relatively unimpeded in human mucus, but the antibody Fc region forms transient, low-
affinity bonds with mucus.111-113 As antibodies accumulate on the surface of a virus, 
multivalent antibody interactions with the mucus mesh can trap the virus.111-113 
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Neutralizing antibodies against AAV2 have been found in approximately 30% of adults 
with CF.114,115 Antibodies against AAV serotypes 1, 5, 6, 7, and 8 have also been found 
in humans, though typically with lower prevalence compared to AAV2.115,116   
Physical obstruction by the sputum biopolymer meshwork can also trap particles. 
In a subset of patient samples, we found that the 100 nm PS-PEG particles, which resist 
adhesion to sputum, were mostly immobilized. This suggests that those samples’ average 
pore size was less than 100 nm. Physical obstruction by the sputum meshwork likely 
contributed greatly to hindering AAV in those samples. Small pores also contribute to 
adhesive trapping, by increasing the probability of multivalent binding interactions 
between AAV and sputum.17 Sputum samples can have a wide range of pore sizes,84 so 
even samples with larger average pore sizes likely have some pores small enough to 
impede AAV motion. 
 We showed that modulating adhesion and physical obstruction may improve 
AAV diffusion in sputum. We tested a mutant AAV2, engineered at two capsid positions 
to have reduced heparin binding, and found that it diffused significantly faster in sputum 
than did AAV2. We attribute the faster transport of the mutant to reduced adhesion to 
heparan sulfate in sputum. A critical consideration is whether the AAV2 capsid 
modification will reduce transduction of polarized airway epithelial cells. Recent research 
shows that heparan sulfate is not essential for AAV2 transduction of airway cells,117 so 
the AAV2 mutant may permit improved sputum penetration without compromising the 
vector’s ability to transduce airway epithelial cells in vivo. Our work provides proof of 
concept that capsid modification may be an effective strategy for improving AAV 
diffusion in sputum, and it motivates further research to design a gene vector that can 
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rapidly penetrate sputum, but is excellent at transducing lung cells in vivo. This may be a 
challenging task in general, given that the binding domains of cell surface receptors 
necessary for AAV transduction may also be present in sputum. A high-throughput 
screen of many AAV mutants may be the best approach to address this challenge.   
We also found that physically altering sputum using the mucolytic drug N-
acetylcysteine, which breaks intermolecular disulfide crosslinks and depolymerizes 
mucins, could markedly improve AAV transport in CF sputum. For some patients, this 
may be a relatively simple and feasible approach for improving gene vector penetration 
in sputum. NAC improved AAV transport by one order of magnitude in three of five 
sputum samples. The two sputum samples that showed little change with NAC treatment 
might have had high mucin content, as we previously found that the effectiveness of 
NAC treatment was inversely correlated with the mucin concentration  – and hence the 
concentration of disulfide bonds – in the sputum sample.84 In a recent review, the CF 
Foundation consensus panel found insufficient evidence that NAC improved CF patients’ 
lung function, so could not recommend for or against its routine use; in contrast, the 
panel did recommend use of recombinant human DNase (dornase alfa, proprietary name 
Pulmozyme®), which acts as a mucolytic by degrading DNA in CF sputum and 
significantly improves pulmonary outcomes.118 For the purpose of improving 
nanoparticle transport in sputum, however, our group previously found that DNase 
treatment alone was ineffective, while NAC treatment was effective.84,104 Even if it is not 
routinely used for CF treatment, NAC could be useful as an adjuvant for AAV gene 
therapy. We did observe a small (~10%) reduction in AAV-mediated transduction of 
BEAS-2B cells when 5 mM NAC was added to the cell culture media. This reduction is 
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small considering that NAC treatment may permit ten-fold more AAV to penetrate 
sputum. Furthermore, we expect that this reduction will be even smaller in the airways, 
where mucins will compete for NAC, as compared to our cell culture experiments, where 
the culture media did not contain mucin.  
Although many of the AAV particles were immobilized in sputum, we found that 
a fraction of them were mobile, with substantial variation among patients. These data 
suggest that sputum may be a greater barrier to AAV gene delivery in some patients than 
in others. We observed a wide range in particle transport among patient samples, in 
agreement with other studies,26 from essentially all particles immobilized to many 
particles diffusive. We reason that a complex interplay between patients’ lung health, 
microbial colonization, mucin biochemistry, and airway hydration determines the 
physicochemical properties of their sputum, and thereby governs the extent to which their 
sputum sterically and adhesively impedes particle diffusion. It would be clinically useful 
to understand the molecular origins of these differences and identify sputum biomarkers 
predictive of AAV transport, but given the complex biochemistry of sputum, such an 
undertaking was beyond the scope of our current investigation.  
We have also shown that labeling AAV with Alexa Fluor dye does not affect the 
virus infectivity or transport in CF sputum. Still, there are limitations to our experimental 
approach. The labeled viruses typically have low fluorescence intensity, and lower 
signal-to-noise ratio results in worse tracking resolution. More broadly, our approach of 
tracking viruses in expectorated sputum samples may not fully mimic the in vivo 
situation. First, the sputum that patients are able to cough out may differ somewhat in 
composition from the secretions coating their airways. Second, airway secretions in vivo 
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sit above the cell-associated periciliary layer,15 which may pose an additional barrier to 
gene delivery. However, recent work shows that the small size of AAV may facilitate 
penetration through the periciliary layer as well.119 Third, while we studied the barrier 
properties of sputum, we did not directly assess how sputum affects AAV 
transduction.91,120 One alternative experimental approach to address this issue would be to 
layer human CF sputum on top of cultured cells, then add AAV above the sputum, and 
assess how the sputum barrier affects transduction. We have found this to be challenging 
in practice because the CF sputum samples tend to infect the cell cultures with bacteria, 
and furthermore, it is difficult to add sputum at a physiologically accurate thickness (on 
the order of tens of µm). Fourth, we conducted the particle tracking experiments in static 
sputum samples, whereas the CF lung is a dynamic environment with at least some 
ciliary activity. In future studies, it would be valuable to study the transport of promising 
gene vectors in both human CF sputum and in the secreted mucus layer on primary 
airway epithelial cells cultured at the air-liquid interface (ALI). The former material more 
closely mimics the secretions lining the diseased CF lung, while the latter approach 
would permit us to study gene vector mobility in a dynamic environment with beating 
cilia. ALI cultures would enable us to experimentally compare the rate at which gene 




In summary, this work quantitatively demonstrated that CF sputum is a significant 
barrier to AAV gene therapy, and showed that capsid modification and the mucolytic 
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adjuvant NAC enhanced AAV diffusion in sputum. In recent years, researchers have 
made promising advances in overcoming various roadblocks to AAV gene therapy, 
including engineering the AAV capsid to increase lung transduction,121 optimizing the 
viral genome to enhance CFTR expression,87 and minimizing immune response to AAV.8 
Our findings emphasize that CF sputum is another roadblock to CF gene therapy, and we 




Table 4.1. Hydrodynamic diameter (nm) of unlabeled vs. Alexa Fluor-labeled AAV 
and PS-PEG particles. 
 unlabeleda  labeleda,b  
AAV1 20 ± 1 19 ± 1 
AAV2 30 ± 1 30 ± 1 
AAV5 21 ± 1 19 ± 1 
AAV2 mutant 28 ± 0.2 28 ± 1 
PS-PEG 128 ± 5 125 ± 1 
 
Abbreviations: AAV, adeno-associated virus; PS-PEG, polystyrene particles coated with 
polyethylene glycol 
aMeasured by dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS. Data 
represents the mean of n = 3 measurements. Error values represent standard deviation.  
bFor these measurements, AAV was labeled with Alexa Fluor 555, rather than Alexa 
Fluor 647 (AF647), which was the dye used for the particle tracking experiments. The 
DLS instrument uses a 633 nm laser, so compounds such as AF647 that strongly absorb 
633 nm light interfere with the size measurement and are incompatible with the 






Table 4.2. Patient demographics for Figures 4.2 and 4.3. 
Age 31 ± 8 
Sex (no. of patients)  
     M 8 
     F 2 
FEV1 (% of predicted value)a 62 ± 27 
FVC (% of predicted value)b 83 ± 23 
CFTR genotype (no. of patients)  
     F508del homozygous 7 
     Other 2 
     Unknown 1 
 
aFEV1 is forced expiratory volume in one second.  
bFVC is forced vital capacity.  
FEV1 and FVC are reported as percent of predicted value for a typical individual. 
Predicted value is a function of age, sex, and height. 










Figure 4.1. Effect of AlexaFluor 647 (AF647) dye labeling on AAV transduction in 
BEAS-2B cells, and on nanoparticle transport in cystic fibrosis (CF) sputum. 
(a-d) BEAS-2B cells transduced (a) with AAV2 or (b) with AF647-labeled AAV2 
(AAV2-AF647) are compared to (c) untreated control cells. The AAV packaged a GFP 
reporter gene; green indicates GFP expression. Scale bars represent 100 µm. (d-e) Flow 
cytometry comparing GFP expression in BEAS-2B cells transduced with AAV2 vs. 
AAV2-AF647. Results shown are (d) mean cell fluorescence, in arbitrary units, and (e) 
percent of cells transduced. Error bars denote standard error of the mean (n = 3). The 
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difference in transduction between AAV2 and AAV2-AF647 is not statistically 
significant. (f-g) Multiple particle tracking in CF sputum samples of (f) 100 nm PS-PEG 
particles vs. (g) 100 nm PS-PEG particles labeled with AF647 (PS-PEG-AF647). Graphs 
show distribution of individual particles’ mean squared displacement (MSD) at a time 
scale of 1 s. Data represents 6 sputum samples, with on average >1500 particles of each 
















Figure 4.2. Transport in CF sputum samples of AAV1, AAV2, and AAV5, compared 
to 100 nm PS-PEG control particles. 
Distribution of individual particle MSD values at a time scale of 1 s for (a) 100 nm PS-
PEG particles, (b) AAV1, (c) AAV2, and (d) AAV5.  Data represents the average of 10 
sputum samples, with each sample equally weighted, and with on average >500 particles 
of each type tracked per sample. Percentage of particles that move rapidly, defined as 






Figure 4.3. Patient-to-patient variation in AAV transport. 
 (a) Box-and-whisker plots of MSD values (at a time scale of 1 s) of AAV1, AAV2, 
AAV5, and 100 nm PS-PEG control particles in sputum samples from 10 CF patients. 
Maximum whisker length is 1.5 times the interquartile range; outliers are shown as dots. 
Patients are numbered in ascending order according to the median MSD of 100 nm PS-
PEG particles in their sputum sample. The dashed line at log10MSD = 0 is a visual aid to 
emphasize fast-moving particles, which we define as log10MSD ≥ 0 at a time scale of 1 s. 
(b) Representative trajectories of AAV1, AAV2, AAV5, and 100 nm PS-PEG control 
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nanoparticles in sputum samples from 3 of the aforementioned 10 CF patients. 
Trajectories show 1 s of motion. The MSDs of the trajectories presented are within the 
























Figure 4.4. Effect of mutation in AAV2 heparin-binding domain. 
a) Effect of soluble heparin on transduction of BEAS-2B cells by AAV2 vs. AAV2 
mutant, which was engineered to reduce heparin binding. GFP expression by transduced 
cells was measured by flow cytometry. Values shown are mean cell fluorescence, relative 
to GFP expression in the absence of soluble heparin, for the respective AAV serotype. 
Error bars indicate standard error of the mean (n ≥ 3). Difference is statistically 
significant (p < 0.01) at 10, 25, and 100 µg/mL. (b) Transport in 17 CF sputum samples 
of AAV2 vs. AAV2 mutant. Each marker represents the median MSD at a timescale of 1 
s in one patient sample. Lines connect pairs of data from the same patient’s sample. 







Figure 4.5. Effect of mucolytic agent N-acetylcysteine (NAC) on AAV1 transport in 
CF sputum, and on AAV1 transduction in BEAS-2B cells. 
(a-b) Multiple particle tracking of AAV1 in CF sputum samples either (a) untreated or (b) 
pre-treated with 5 mM NAC. Graphs show distribution of individual particles’ MSDs at a 
time scale of 1 s. Data represents 5 sputum samples, with on average >900 AAV particles 
tracked per sample. Percentage of particles that move rapidly, defined as log10MSD ≥ 0 at 
a time scale of 1 s, is shown for both conditions (dashed boxes). The sputum samples 
used for the NAC study were different than the sputum samples used for Figures 4.2 and 
4.3, and thus the percentage of fast AAV1 particles differs between Figures 4.2b and 
4.5a. (c) Effect of 5 mM NAC in the cell culture media on AAV1 transduction of BEAS-
2B cells. Results show mean cell GFP fluorescence, measured by flow cytometry, in 





Figure 4.6. (Supplementary) Scanning electron micrograph of CF sputum. 








Figure 4.7. (Supplementary) Transport of polymeric nanoparticles in CF sputum. 
Distribution of individual particle mean squared displacements at a time scale of 1 s for 
(a) 100 nm PS-PEG, (b) 100 nm PS-COOH, and (c) 500 nm PS-PEG. Data is from the 
same 10 sputum samples as shown in Fig 2. Data represents the average of the 10 sputum 
samples, with each sample equally weighted. Percentage of particles that move rapidly, 









Figure 4.8. (Supplementary) Diffusion of AAV in water. 
 (a) Distribution of individual particle MSD values at a time scale of 1 s for AAV 
diffusing in water. This data was generated by simulating the random walks39 of 10,000 
particles of diameter 25 nm in 20 ºC water, with each trajectory 1 s long. Percentage of 
particles that move rapidly, defined as log10MSD ≥ 0 at a time scale of 1 s, is shown 
(dashed boxes). (b) The same data, shown as a box-and-whisker plot. Maximum whisker 






Figure 4.9. (Supplementary) Intra- and inter- sputum sample heterogeneity. 
Box-and-whisker plots of MSD values (at a time scale of 1 s) of 100 nm PS-PEG 
particles in four aliquots from each of nine CF patient sputum samples. These are the 
same patient samples as in Figure 4.3. We were unable to collect the data for patient 3. 
Maximum whisker length is 1.5 times the interquartile range; outliers are shown as dots. 
The dashed line at log10MSD = 0 is a visual aid to emphasize fast-moving particles, 
which we define as log10MSD ≥ 0 at a time scale of 1 s. The 100 nm PS-PEG data shown 











Figure 4.10. (Supplementary) Heparin-binding assay. 
Effect of soluble heparin on transduction of BEAS-2B cells by AAV1, AAV2, and 
AAV5. GFP expression was measured by flow cytometry. Values shown are relative to 
GFP expression in the absence of soluble heparin for the respective AAV serotype. Error 




5.  CONCLUSION AND FUTURE OUTLOOK 
 
5.1. Conclusion 
In this dissertation, we used nanoparticles to probe the microstructure of human 
respiratory mucus and CF sputum, and we determined design criteria for nanomedicine 
capable of overcoming the lung mucus barrier. We discovered that 200 nm particles and 
smaller can efficiently penetrate lung mucus if the particles have minimally-adhesive 
surfaces. For polymeric nanoparticles, we achieved this by densely coating the particle 
surface with polyethylene glycol, a hydrophilic polymer widely used in medical and 
household products. Furthermore, we discovered that CF sputum is a tenacious barrier to 
AAV gene vectors, and this barrier likely contributed to the disappointing results of the 
six CF clinical trials that used AAV2. We found that modifying the virus surface to 
reduce adhesion improved its transport, as did chemically modulating the mucus structure 
itself. These findings lay the groundwork for further studies on diffusion of novel 
nanoparticles and viral vectors in lung mucus. Such studies will be critical to the 
development of efficacious nanomedicines for cystic fibrosis and other lung diseases. 
 
5.2. Next steps 
One strength of this work is that we used freshly collected human mucus samples, 
rather than reconstituted mucins, frozen specimens, or (non-human) animal mucus. This 
allowed us to more closely mimic the in vivo mucus barrier. However, our experimental 
system did not incorporate the effects of the pericilary layer or ciliary activity on drug 
and gene delivery to the lungs. This would be worthwhile to study via complementary 
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techniques, such as tracking particles on mucus-secreting human primary cells cultured at 
the air-liquid interface.  
In the CF sputum studies, intra-sample variation poses a challenge when 
comparing transport rates of multiple AAV serotypes or particle types tracked in different 
sputum aliquots. One way to address this challenge is to test large numbers of patient 
samples, as in Chapter 4. In designing future experiments, a rigorous assessment of 
power and sample size would be valuable. Another approach would be to label particles 
with different colors of fluorophores so they can be imaged in the same field of view. We 
used this approach for polystyrene particles, but for AAV we were only able to image the 
virus when it was labeled with dark red dye, as autofluorescence overwhelmed the signal 
when green or red fluorescent dyes were used. New labeling protocols may yet permit 
AAV to be brightly labeled in various colors. Finally, more careful sputum sample 
collection or experimental techniques may reduce aliquot-to-aliquot variation.  
The results in this thesis suggest that in future CF clinical trials, patients should 
try to clear their lungs of sputum to the greatest extent possible prior to delivery of the 
gene vector. This may involve hypertonic saline, mucolytics, and chest physical therapy, 
all of which are routinely used in CF care. On a related note, another valuable lab study 
would be to follow patients over time and track gene vector motion in the patients’ 
sputum at multiple time points. This could identify if there are times (e.g., seasonal or 
following treatment of an exacerbation) when a patient’s sputum would be most 
permissive to gene vector diffusion. Other adjuvants that may enhance AAV penetration 
in sputum are also worth exploring. For instance, pre-treatment of sputum with sialidase 
101 
 
(neuraminidase), which catalyzes hydrolysis of terminal sialic acids, may enhance the 
transport of AAV1 and AAV5, which bind to sialic acids.  
 
5.3. Future outlook 
5.3.1. Advanced microscopy techniques for particle tracking 
Recent years have seen exciting innovations in light microscopy, many of which 
can be harnessed for improved particle tracking. Examples include microscope 
configurations that reduce background fluorescence and technologies that enable tracking 
in three dimensions (3D). Although these techniques often require custom 
instrumentation, some are already commercially available. 
 Light sheet fluorescence microscopy, also called selective plane illumination 
microscopy, has been attracting increasing interest recently as a technique to achieve 
reduced background fluorescence when imaging deep in large biological specimens.122 
This technique requires two objective lenses oriented orthogonally to each other. One 
objective is used to form a thin light sheet, which illuminates only a narrow plane of the 
specimen, and thus background fluorescence is reduced. The other objective, 
perpendicular to the light sheet, is used for detection. Light sheet microscopy can thus 
achieve optical sectioning, similar to confocal microscopy, but with less photobleaching 
and faster acquisition rates. A number of recent papers report improved signal-to-noise 
ratio, and good spatial and temporal resolution, using light sheet microscopy-based 
particle tracking.123-126 
Typically, particles are only tracked in the two lateral dimensions (x and y). A 
range of approaches now exist for also localizing particles in the axial (z) dimension to 
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obtain 3D trajectories, which are useful for studying anisotropic motion.31,127 One 
approach is to collect z-stacks with confocal microscopy, but even with a spinning disk 
confocal microscope, the temporal resolution is insufficient for tracking fast particles. A 
second approach is to track a single particle at a time, keeping it in focus as it moves by 
adjusting the height of the stage or the objective lens using a feedback system.127-129 A 
third class of approaches exploits changes in the particle image as the particle goes in and 
out of focus: A fluorescent particle in focus appears as a compact Gaussian spot, whereas 
diffraction rings become visible when the particle lies more than a few hundred 
nanometers from the focal plane. The particle image thus encodes information about the 
particle position in z. Even with a standard microscope, this information may be used to 
approximate the height of the particle.2,37 To obtain better precision in z, a number of 
microscope configurations have been invented to engineer the point spread function so 
that the particle image varies strongly, and in a predictable way, as the particle distance 
from the focal plane varies. This can be accomplished by placing additional optical 
elements, such as a cylindrical lens, in the light path.130-132 Alternatively, the microscope 
can be configured to image multiple planes of the specimen at once, from which the 
particle position in z can be calculated.133-135 
 
5.3.2. Future use of particle tracking in drug and gene delivery research 
The approaches used in this thesis are broadly applicable to drug and gene 
delivery research. Nanoparticles hold great promise as vectors for efficacious drug and 
gene delivery, but they encounter numerous barriers in the body prior to reaching their 
delivery targets. Particle tracking is a powerful technique for characterizing the behavior 
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of nanoparticles and how effectively they overcome extracellular and cellular 
barriers. Thus, future applications of particle tracking in drug and gene delivery research 
are nearly as broad as the field of nanomedicine itself. Looking ahead, we envision the 
implementation of high-throughput particle tracking studies to test libraries of 
nanoparticle formulations in biological samples of interest, such as blood, mucus, or 
tissue. Such a screening technique will allow for rapid identification of nanoparticle 
formulations that are likely to exhibit favorable in vivo delivery and warrant further 
development. Intravital particle tracking, which is just starting to become possible thanks 
to advances in imaging techniques, may also revolutionize drug and gene delivery 
research. The ability to directly observe the journey of a nanoparticle in vivo will provide 








APPENDIX: AUTOMATED PARTICLE TRACKING CODE IN MATLAB 
 
This particle tracking code uses the algorithm of Crocker and Grier,2 which was 
originally written in the IDL language. Some functions were based on earlier MATLAB 
versions by Daniel Blair, Eric Dufresne, and Maria Kilfoil. The code consists of one main 
script, where the user inputs a few required parameters, and function files that the user 
does not need to modify. Explanatory comments in the code are colored green. 
Two user-input parameters are especially important. They are as follows: 
1. maxdisp: The largest distance (in pixels) that a particle could travel from one frame to 
the next. It must be less than the mean spacing between particles. This value can be 
estimated by scrolling through the movie and observing the frame-to-frame jumps. 
2. lobject: The diameter of the particles in pixels. This number should be just large 
enough to capture the whole particle. 
The algorithm is described in greater detail in Chapter 2. In brief, the code does 
the following:  
1. Load movie. 
2. Discard bad regions of movie (such as debris or aggregates) if necessary. 
3. Process image using bandpass filter. 
4. Identify local maxima, which are initial estimates of candidate particle positions. 
5. Refine position estimates by calculating the particles’ intensity-weighted centroids. 
6. Discard spurious particles, and keep real ones, based on their size, brightness, and 
eccentricity. 
7. Link x and y positions over time into trajectories. 




clear; clc; close all; 
  
% Purpose: Front-end/interface for automated particle tracking. User sets 
% parameters and runs code from here. This file calls functions to input the 
% movies, process them, and output the results. 
% 
% The tracking algorithm implemented here is from Crocker and Grier 
% (J Coll Interf Sci, 1996). Some parts of the code were adapted from Blair 
% and Dufresne and from Kilfoil. 
% 
% Benjamin Schuster, JHU, 2012-2014. 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% User input 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% User input - directory and movie extension 
dir = 'C:\Users\Benjamin\Desktop\MPT in agarose'; 
ext = '.tif'; % for grayscale .tif videos from fluorescence microscopy 
% ext = '.mov'; % for 8-bit RGB avi files from transmitted light microscopy 
  
% User input - parameters for each group of movies (ex, different particle types) 
% The code can be run on 1 or multiple groups of movies. Simplest to just 
% do one group at a time. 
numGroups = 1; 
groupinfo(1).group = '20130802 s2 500'; %base name of movies in group 
groupinfo(1).spacer = ' '; %space or other character between group name and movie number 
groupinfo(1).nMovies = 2; %# of movies in group; movies must be labeled sequentially starting at 1 
groupinfo(1).lobject = 9; %approx size of particle in pixels - must be odd, preferably >= 7 
groupinfo(1).maxdisp = 4; %max displacement of particle from one frame to next  
groupinfo(1).startframe = [1 5]; %first frame to track. one # per movie, separated by commas or spaces. 
groupinfo(1).stopframe = [50 100]; %last frame to track. one # per movie, separated by commas or spaces. 
  
% User input - camera frame rate. 
% Note: The code assumes all the movies being processed at a time are at 
% the same frame rate. 
fpers_user = 25; %Hz 
  
% User input - tracking parameters 
% Recommendation: Set min_frames low (ex 10) for now, and during post-processing 
% you can set it higher if desired 
memory_nframes = 3; %number of consecutive frames a particle can go out of view and be tracked  
% as the same particle 
min_frames = 15; % eliminate trajectories with fewer than this number of frames 
  
% User input - microscope conversion factor 
scope_conv = 0.2457; %um/pixel, for Hanes Lab AxioObserver 100x objective 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% Optional user input 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% Bandpass filter parameters 
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lnoise = 1; %almost always keep this at 1 
  
% Thresholding/particle discrimination method 
% method = 1 for method of Crocker and Grier, using particle "mass," 
%  radius, and eccentricity. Slower but more sensitive method. Set for 
%  each movie. Recommended. 
% method = 2 for simple thresholding method, from Blair and Dufresne's 
%  MATLAB tracking code. Faster, but less flexible and sensitive. 
% method = 3 for time-saving method : set the parameters for the first movie 
%  using the Crocker-Grier approach, then use those settings for all the 
%  movies in a group. 
particleDiscriminationMethod = 1; 
  
% If particleDiscriminationMethod is 1 or 3, require particle candidates to 
% be in upper cut_percentile percentile of brightness. This should be 
% large enough that you don't exclude any true particles. But too large 
% and you waste time calculating centroids of noise spots. In my experience, 
% 0.05 is more than large enough for most movies. Even 0.01 fine for many 
% movies. (Note: Crocker and Grier paper used 0.3). 
cut_percentile = 0.03; 
  
% format of output movie 
%movieprofile = 'MPEG-4'; %Compressed MPEG-4 file (Windows 7 only) - small file, lower quality 
movieprofile = 'Uncompressed AVI'; %Uncompressed AVI file - large file, high quality 
  
% display output movie 
movie_display = 1; % display the output movie as it's written. Note: may capture screensaver if it turns on! 
% movie_display = 0; % does not display the output movies as it's written. But it's still saved to disk. 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% User should not adjust code beyond here. 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% display current time 
disp(['Starting time: ' datestr(now)]) 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Load movie info 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
% data structures for storing info used in processing the movies 
maxNumMovies = 0; 
for gp = 1:numGroups 
    if groupinfo(gp).nMovies > maxNumMovies 
        maxNumMovies = groupinfo(gp).nMovies; 
    end 
end 
filenames = cell(numGroups,maxNumMovies); 
movieInfos = cell(numGroups,maxNumMovies); 
numRgns2Exclude = zeros(numGroups,maxNumMovies); 
roiVerticesX = cell(numGroups,maxNumMovies); 
roiVerticesY = cell(numGroups,maxNumMovies); 
InvertedMasks = cell(numGroups,maxNumMovies); 
thresholds = zeros(numGroups,maxNumMovies); 
poly_verts = cell(numGroups,maxNumMovies); 




% Load movie info, select regions to exclude, and choose threshold 
% Reason for having a separate loop for this, rather than combining with 
% the main feature finding and tracking loop: If there are any problems 
% with loading or removing bad regions from one of the later movies in a 
% group, you indentify that problem before doing all the tracking on the 
% earlier movies. 
for gp = 1:numGroups 
     
    group = groupinfo(gp).group; 
    spacer = groupinfo(gp).spacer; 
    numMovies = groupinfo(gp).nMovies; 
    lobject = groupinfo(gp).lobject; 
     
    for mvnum = 1:numMovies 
         
        startf =  groupinfo(gp).startframe(mvnum); 
        stopf = groupinfo(gp).stopframe(mvnum); 
         
        %load movie info 
        [filename,movieInfo,fpers] = loadMovieInfo_dissertation(dir,group,spacer,mvnum,ext,fpers_user); 
        filenames{gp,mvnum} = filename; 
        movieInfos{gp,mvnum} = movieInfo; 
         
        %choose regions to exclude, such as cells or aggregated particles that cause erroneous tracking 
        [nRgn2Exclude,xVert,yVert,invertedMask,im1,im1bp] = ... 
regions2exclude_dissertation(movieInfo,filename,lnoise,lobject,ext,startf,stopf); 
        numRgns2Exclude(gp,mvnum) = nRgn2Exclude; 
        roiVerticesX{gp,mvnum} = xVert; 
        roiVerticesY{gp,mvnum} = yVert; 
        InvertedMasks{gp,mvnum} = invertedMask; 
         
        %threshhold 
        % In method 1 and 3, thresholding is a preliminary step, further refinement later 
        % In method 2, this is how to select background from noise 
        if particleDiscriminationMethod == 1 || particleDiscriminationMethod == 3  
            s = sort(im1bp(:),'descend');  % thresholding based on first frame; could change to last frame 
            [dim1,dim2] = size(im1bp); 
            cut_index = round(dim1*dim2*cut_percentile); 
            thresholds(gp,mvnum) = s(cut_index); 
        elseif particleDiscriminationMethod == 2  
            thresholds(gp,mvnum) = 
simplethresh_dissertation(filename,nRgn2Exclude,xVert,yVert,im1,im1bp); 
        end 
         
    end 
end 
disp('Movie information successfully loaded.') 
close all 
  
% setting for one of the output figures 
scrnsize = get(0,'ScreenSize'); 
figpos1 = [100 100 1000 500]; 
if (figpos1(1)+figpos1(3))>scrnsize(3) || (figpos1(2)+figpos1(4))>scrnsize(4) 






% Do particle detection and tracking 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
lastline = zeros(numGroups,maxNumMovies); 
for gp = 1:numGroups % loop over the groups 
    group = groupinfo(gp).group; 
    numMovies = groupinfo(gp).nMovies; 
     
    %particle identification and tracking parameters 
    lobject = groupinfo(gp).lobject; 
    pkfindsz = lobject; 
    cntrdsz = lobject; 
    %Blair and Dufresne recommended cntrdsz = lobject+2, but this could cause 
    %a problem where the brightest pixel is at the edge, not the center, of 
    %the ROI for calculating the centroid when there are two particles close 
    %together or if there are diffraction rings. 
    maxdisp = groupinfo(gp).maxdisp; 
     
    %structring element for imdilate, used in pkfnd 
    SE = strel('disk', ceil(pkfindsz/2)); % input into strel is radius of structuring element. 
    %SE = strel('disk', ceil(pkfindsz/2),0) % the 0 gives you an exact disk 
    %rather than an approximation, but it makes imdilate a bit slower 
     
    %cell arrays for storing the data 
    SNRCell = cell(numMovies,1); % for storing signal-to-noise ratio 
    TrajGroupCell = cell(numMovies,1); % for storing all trajectories from 1 group of movies 
    TrajStart0GroupCell = cell(numMovies,1); % as above, but trajectory position 
    % starts at 0 (i.e. displacements relative to initial position) 
     
    for mvnum = 1:numMovies % loop over all the movies in a group 
        filename = filenames{gp,mvnum}; 
        display([filename ' - analyzing']) 
        movieInfo = movieInfos{gp,mvnum}; 
        thresh = thresholds(gp,mvnum); 
         
        %first and last frames of the movie to analyze 
        startf =  groupinfo(gp).startframe(mvnum); 
        stopf = groupinfo(gp).stopframe(mvnum); 
        num_images = stopf-startf+1; 
         
        if strcmp(ext,'.mov') 
            movieobj = VideoReader(filename); 
        end 
         
        cntAllcell = cell(num_images,1); %for storing particle centroids and data (brightness etc.) 
         
        noisemean = zeros(1,num_images); 
        noisestd = zeros(1,num_images); 
        signal = zeros(1,num_images); 
         
        % Locate particles 
        tic %start timing 
        for i = startf:stopf % loop over desired frames in a movie 
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            %Load in one frame.  
            if strcmp(ext,'.tif') 
                im = imread(filename, 'tif', i, 'Info', movieInfo); %Info speeds imread for multi-image tiff 
            elseif strcmp(ext,'.mov') 
                moviecdata = read(movieobj,i); 
                im = 256*3 - sum(moviecdata,3); 
            end 
            im = double(im); % im needs to be a double for convolution in bpass 
             
            %Spatial bandpass filter smooths the image and subtracts the background off 
            imbp = bpass_dissertation(im,lnoise,lobject); 
             
            %Remove excluded regions, if any 
            imbp = imbp.*InvertedMasks{gp,mvnum}; 
             
            %Identify the candidate particle locations to pixel-level accuracy. 
            [pk,noisemean(i-startf+1),noisestd(i-startf+1)]=pkfnd_dissertation(im,imbp,thresh,SE); 
             
            % Refine location estimate by calculating particle centroid. 
            cnt = cntrd_dissertation(imbp,pk,cntrdsz); 
            % Each row in cnt stores the data on one particle (spot). 
            % cnt has 5 columns. They are: 1. x-coordinates, 2. y-coordinates, 
            % 3. brightnesses, 4. square of radius of gyration, 5. eccentricity 
             
            % In 6th column, add frame number with respect to the first frame 
            % tracked. I.e., if we're tracking frames 10 and onwards, frame 10 
            % is the first frame tracked and will be recorded here with a 
            % "frame stamp" of 1. So frame_stamp = trueframe#-startf+1 
            if numel(cnt) > 0 
                cntAllcell{i-startf+1} = [cnt (i-startf+1)*ones(size(cnt,1),1)]; 
            end 
             
            mo = mod(i,25); 
            if mo == 0 
                disp(['centroid finding - completed frame ' num2str(i)]) 
            end 
             
        end 
        cntAll = cell2mat(cntAllcell); 
        toc %finish timing the centroid finding 
         
        % discriminate true particles from noise 
        if particleDiscriminationMethod == 1 
            [pos,eccen_cuts(gp,mvnum)] = 
particleDiscrimination_dissertation(num_images,cntAll,im,filename,lobject); 
        elseif particleDiscriminationMethod == 2 
            pos=cntAll; 
        elseif particleDiscriminationMethod == 3 
            if gp == 1 && mvnum == 1 
                [pos,brightness_cut,eccen_cut] = ... 
batchParticleDiscrimination_dissertation(num_images,cntAll,im,filename,lobject); 
            else 
                rows2keep = cntAll(:,3) >= brightness_cut; 
                cntAllKeep = cntAll(rows2keep,:); 
                rows2keep = cntAllKeep(:,5) <= eccen_cut; 
                disp([num2str(size(cntAllKeep,1)) ' spots kept']) 
110 
 
                pos = cntAllKeep(rows2keep,:); 
            end 
        end 
         
        % Calculating approximate signal-to-noise ratio (Savin and Doyle, 
        % Biophys J, 2005) 
        disp('Calculating approximate signal-to-noise ratio') 
        for i = startf:stopf 
            pix = round(pos(pos(:,6) == (i-startf+1),1:2)); % bright pixels 
            %Load in one frame 
            if strcmp(ext,'.tif') 
                im = imread(filename, 'tif',i, 'Info', movieInfo); %Info speeds imread for multi-image tiff 
            elseif strcmp(ext,'.mov') 
                moviecdata = read(movieobj,i); 
                im = 256*3 - sum(moviecdata,3); 
            end 
            im = double(im); 
            idx = sub2ind(size(im), pix(:,2), pix(:,1)); 
            signal(i-startf+1) = mean(im(idx)); 
        end 
        SNR = (signal-noisemean)./noisestd; %note, there are other definitions of SNR 
        figure 
        plot(startf:stopf,SNR) 
        xlabel('frame number') 
        ylabel('signal/noise') 
        title('Approximate signal-to-noise raio') 
        set(gca,'YLim',[0 1.1*max(SNR)]) 
        SNRCell{mvnum} = [startf:stopf; SNR]'; 
         
        % Check for pixel bias, i.e. check for sub-pixel feature location. 
        % Histograms of the x and y-positions modulo 1 should be flat IF you 
        % have enough particles and they are not single pixel biased. 
        f = figure('name','Check for pixel bias. Histograms should be flat if you have sub-pixel localization.'); 
        set(f,'Position',figpos1) 
        subplot(1,2,1) 
        hist(mod(pos(:,1),1),20) 
        ylabel('count') 
        xlabel('x coordinates modulo 1') 
        subplot(1,2,2) 
        hist(mod(pos(:,2),1),20) 
        ylabel('count') 
        xlabel('y coordinates modulo 1') 
        print(f,[filename(1:end-4) ' - pixel bias check.jpg'],'-djpeg') 
         
        % Trajectory linking step: connect the list of particle positions into trajectories 
        tic % begin timing 
        Traj = mytracker_dissertation(pos,maxdisp,memory_nframes,min_frames); 
        num_particles = max(Traj(:,1)); 
        disp([num2str(num_particles) ' trajectories']) 
        toc % end timing 
         
        % Compute trajectories with respect to initial position 
        TrajStart0 = zeros(size(Traj,1),4); 
        X = NaN(num_images,num_particles); %this will be used for making the trajectory movie 
        Y = NaN(num_images,num_particles); %this will be used for making the trajectory movie 
        for j = 1:num_particles 
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            rows = find(Traj(:,1)==j); 
            frms = Traj(rows,2); %not frms-startf+1, because of how frame numbers are are counted in Traj 
            x = Traj(rows,3); 
            y = Traj(rows,4); 
             
            X(frms,j) = x; 
            Y(frms,j) = y; 
             
            x2 = x - x(1); 
            y2 = y - y(1); 
            TrajStart0(rows,1) = j; 
            TrajStart0(rows,2) = 1:length(x); 
            TrajStart0(rows,3) = x2; 
            TrajStart0(rows,4) = y2; 
        end 
        Traj(:,2) = Traj(:,2) + (startf-1); % now that the caclculations are 
        % done, add this back so in Traj frame number is absolute, not relative 
        % to the first frame tracked. Leave TrajStart0 as is. 
        TrajGroupCell{mvnum} = Traj; 
        TrajStart0GroupCell{mvnum} = TrajStart0; 
        if mvnum == 1 
            lastline(gp,mvnum) = size(Traj,1); 
        else 
            lastline(gp,mvnum) = lastline(gp,mvnum-1) + size(Traj,1); 
        end 
         
        % Make movie with trajectories overlayed 
        xVert = roiVerticesX{gp,mvnum}; 
        yVert = roiVerticesY{gp,mvnum}; 
        nRgn2Exclude = numRgns2Exclude(gp,mvnum); 
        tic 
        makeTrajectoryMovie_dissertation(filename,ext,movieprofile,  
...fpers,movie_display,movieInfo,X,Y,xVert,yVert,nRgn2Exclude,startf,stopf); 
        toc 
        disp(['Movie ' filename ' done']) 
    
    end 
    TrajGroup = cell2mat(TrajGroupCell); 
    TrajStart0Group = cell2mat(TrajStart0GroupCell); 
     
    % calculate the MSD 
    [TrajProc,Timescale,num_particles,frames] = process_MPT_data_dissertation(TrajStart0Group,fpers); 
    [MSD,MSDx,MSDy,d_shortest_t,num_displacements] = ... 
calculate_MSD_dissertation(TrajProc,Timescale,num_particles,frames,scope_conv); 
     
    %plot the number of displacements as a function of time scale 
    figure 
    plot(Timescale,sum(num_displacements,2)) 
    xlabel('time (s)') 
    ylabel('number of displacements') 
     
    % calculate the ensemble MSD - note ensemble averaging isn't 
    % recommended when there are distinct categories of particles, e.g. 
    % immobile and mobile, in the same data set 
    frm_max = size(MSD,1); 
    meanMSD = zeros(frm_max,1); 
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    meanMSDx = zeros(frm_max,1); 
    meanMSDy = zeros(frm_max,1); 
    for f = 1:frm_max 
        meanMSD(f) = mean(MSD(f,~isnan(MSD(f,:)))); % arithmetic mean 
        meanMSDx(f) = mean(MSDx(f,~isnan(MSDx(f,:)))); 
        meanMSDy(f) = mean(MSDy(f,~isnan(MSDy(f,:)))); 
    end 
     
    % plot the MSD vs. time scale 
    f1 = figure; 
    set(f1,'Position',figpos1) 
    subplot(1,2,1) 
    loglog(Timescale,meanMSDx,Timescale,meanMSDy,Timescale,meanMSD); 
    legend('MSDx','MSDy','MSD','location','northwest') 
    title('ensemble-average MSD (arithmetic mean) - log axes') 
    xlabel('Timescale (s)') 
    ylabel('<MSD> (\mum^2)') 
    subplot(1,2,2) 
    plot(Timescale,meanMSDx,Timescale,meanMSDy,Timescale,meanMSD); 
    legend('MSDx','MSDy','MSD','location','northwest') 
    title('ensemble-average MSD (arithmetic mean) - linear axes') 
    xlabel('Timescale (s)') 
    ylabel('<MSD> (\mum^2)') 
    print(f1,[dir '\' group ' - MSD plot.jpg'],'-djpeg') 
     
    %check that maxdisp is large enough 
    f2 = figure; 
    hist(d_shortest_t,20) 
    xlabel('displacement at shortest time scale (1 frame)') 
    ylabel('count') 
    title(['Check that maxdisp = ' num2str(maxdisp) ' is large enough']) 
    print(f2,[dir '\' group ' - maxdisp check.jpg'],'-djpeg') 
     
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    % export data to Excel - one file for trajectories, another for MSDs       
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
     
    group = groupinfo(gp).group; 
    spacer = groupinfo(gp).spacer; 
    display(['Exporting data to Excel for ' group]) 
     
    tic %begin timing hohw long it takes to output the data 
    outputfile = [dir '\' group ' - ' num2str(mvnum) ' movies auto tracked - Trajectories.xlsx']; 
    xlswrite(outputfile,TrajStart0Group,'Sheet1','A1') 
    % Sheet 1 contains the trajectories, one row for each particle position. 
    % The columns are 1. particle number 2. frame number 
    % 3. x-coordinates, 4. y-coordinates. Here the x and y coordinates are 
    % given in pixel units, with respect to the initial particle position. 
    TrackingSettings{1,1} = 'tracker driver version'; 
    TrackingSettings{1,2} = mfilename; 
    TrackingSettings{2,1} = 'min_frames'; 
    TrackingSettings{2,2} = min_frames; 
    TrackingSettings{3,1} = 'memory_nframes'; 
    TrackingSettings{3,2} = memory_nframes; 
    TrackingSettings{4,1} = 'maxdisp'; 
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    TrackingSettings{4,2} = maxdisp; 
    TrackingSettings{5,1} = 'lobject'; 
    TrackingSettings{5,2} = lobject; 
    TrackingSettings{6,1} = 'pkfindsz'; 
    TrackingSettings{6,2} = pkfindsz; 
    TrackingSettings{7,1} = 'cntrdsz'; 
    TrackingSettings{7,2} = cntrdsz; 
    TrackingSettings(9,1:2) = {'filename';'last line of trajectories'}; 
    TrackingSettings(10:(9+numMovies),1) = filenames(gp,:)'; 
    TrackingSettings(10:(9+numMovies),2) = mat2cell(lastline(gp,:)',ones(numMovies,1)); 
    xlswrite(outputfile,TrackingSettings,'Sheet2','A1') 
    % Sheet 2 contains the tracking settings 
    xlswrite(outputfile,TrajGroup,'Sheet3','A1') 
    % Sheet 3 contains the trajectories, one row for each particle position. 
    % The columns are 1. particle number 2. frame number 
    % 3. x-coordinates, 4. y-coordinates, 5. brightnesses, 6. square of 
    % radius of gyration, 7. eccentricity. Here the x and y coordinates are 
    % in absolute pixel numbers (not with respect to the initial particle 
    % position) 
     
    % The next file contains 
    % In Sheet 1: Column with timescale (units: s), column with ensemble MSD, 
    % blank column, then columns with individual particles MSDs (MSD units: um^2). 
    % In Sheet 2: The signal-to-noise ratio for each frame analyzed 
    outputfile = [dir '\' group ' - ' num2str(mvnum) ' movies auto tracked - MSD.xlsx']; 
    xlswrite(outputfile,[Timescale' meanMSD NaN(length(Timescale),1) MSD],'Sheet1','A1')     
    xlswrite(outputfile,cell2mat(SNRCell),'Sheet2','A1') 
    toc 
     
end 
  
%display current time 
disp(['Ending time: ' datestr(now)]) 
 
 
Function for loading videos 
 
function [filename,movieInfo,fpers] = loadMovieInfo_dissertation(dir,group,spacer,mvnum,ext,fpers_user) 
  
% Loads the movie information and calculates the frame rate, then checks that 
% it agrees with the user-input frame rate. 
% 
% Benjamin Schuster, JHU, 2012-2014 
   
filename = [dir '\' group spacer num2str(mvnum) ext]; 
display([filename ' - loading movie information']) 
  
if strcmp(ext,'.tif') 
     
    movieInfo = imfinfo(filename); 
     
    if isfield(movieInfo,'DateTime') 
        %frame rate calculation - calculate from movie info 
        time1 = str2double(movieInfo(1).DateTime((end-5):end)); 
        time2 = str2double(movieInfo(2).DateTime((end-5):end)); 
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        exposureTime = time2 - time1; 
        if isnan(exposureTime) %get NaN if hour just changed, so try again 
            time1 = str2double(movieInfo(5).DateTime((end-5):end)); 
            time2 = str2double(movieInfo(6).DateTime((end-5):end)); 
            exposureTime = time2 - time1; 
        end 
        fpers = round(1/exposureTime); 
        if fpers_user == fpers 
            disp(['Calculated and input frame rates agree: ' num2str(fpers) ' Hz']) 
        else 
            disp(['Frame rate calculated (rounded to whole number): ' num2str(fpers) ' Hz']) 
            disp(['Frame rate entered by user: ' num2str(fpers_user) ' Hz']) 
            disp('Frame rate discrepancy! Will use calculated frame rate. Please check movie.') 
        end 
    else 
        disp('Cannot calculate frame rate from movie. Will use user-input value.') 
        fpers = fpers_user; 
    end 
     
elseif strcmp(ext,'.mov') 
     
    movieInfo = VideoReader(filename); 
     
    % nFrames = movieobj.NumberOfFrames; 
    % vidHeight = movieobj.Height; 
    % vidWidth = movieobj.Width; 
    fpers = movieInfo.FrameRate; 




Function for selecting regions of a video to discard 
 
function [nRgn2Exclude,xVert,yVert,invertedMask,im1,im1bp] = ... 
    regions2exclude_dissertation(movieInfo,filename,lnoise,lobject,ext,startf,stopf) 
  
% This function allows you to avoid tracking certain undesired areas, 
% such as debris or aggregates, that can cause erroneous tracking. 
  
% Benjamin Schuster, JHU, 2012-2014 
  
display([filename ' - user input']) 
  
scrnsize = get(0,'ScreenSize'); 
figpos1 = [200 200 1200 700]; 
if (figpos1(1)+figpos1(3))>scrnsize(3) || (figpos1(2)+figpos1(4))>scrnsize(4) 
    figpos1 = [0 0 .75*scrnsize(3) .75*scrnsize(4)]; 
end 
  
w = movieInfo(1).Width; %width is number of columns 
h = movieInfo(1).Height; %height is number of rows 
im = zeros(h,w,4); 
imbp = zeros(h,w,4); 
  




    movieobj = VideoReader(filename); 
end 
imnums = floor(linspace(startf,stopf,4)); 
for i = 1:4 
    if strcmp(ext,'.tif') 
        im(:,:,i) = double(imread(filename, imnums(i),'Info', movieInfo)); 
    elseif strcmp(ext,'.mov') 
        moviecdata = read(movieobj,imnums(i)); 
        im(:,:,i) = 256*3 - sum(moviecdata,3); 
    end 
    imbp(:,:,i) = bpass_dissertation(im(:,:,i),lnoise,lobject); 
end 
fig = figure('name',[filename ': selected raw and bandpassed images']); 
set(fig,'Position', figpos1) 
ax1 = axes('position',[.04 .55 .2 .35],'units','normalized'); 
ax2 = axes('position',[.28 .55 .2 .35],'units','normalized'); 
ax3 = axes('position',[.52 .55 .2 .35],'units','normalized'); 
ax4 = axes('position',[.76 .55 .2 .35],'units','normalized'); 
ax5 = axes('position',[.04 .1 .2 .35],'units','normalized'); 
ax6 = axes('position',[.28 .1 .2 .35],'units','normalized'); 
ax7 = axes('position',[.52 .1 .2 .35],'units','normalized'); 
ax8 = axes('position',[.76 .1 .2 .35],'units','normalized'); 
imagesc(im(:,:,1),'Parent',ax1); 
title(['frame ' num2str(imnums(1))],'Parent',ax1) 
imagesc(im(:,:,2),'Parent',ax2); 
title(['frame ' num2str(imnums(2))],'Parent',ax2) 
imagesc(im(:,:,3),'Parent',ax3); 
title(['frame ' num2str(imnums(3))],'Parent',ax3) 
imagesc(im(:,:,4),'Parent',ax4); 
title(['frame ' num2str(imnums(4))],'Parent',ax4) 
imagesc(imbp(:,:,1),'Parent',ax5); 
title(['bandpass filtered frame ' num2str(imnums(1))],'Parent',ax5) 
imagesc(imbp(:,:,2),'Parent',ax6); 
title(['bandpass filtered frame ' num2str(imnums(2))],'Parent',ax6) 
imagesc(imbp(:,:,3),'Parent',ax7); 
title(['bandpass filtered frame ' num2str(imnums(3))],'Parent',ax7) 
imagesc(imbp(:,:,4),'Parent',ax8); 
title(['bandpass filtered frame ' num2str(imnums(4))],'Parent',ax8) 
colormap('gray') 
  
%select regions to exclude, if any 
nRgn2Exclude = []; 
while isempty(nRgn2Exclude) 
    try 
        nRgn2Exclude=input('If you wish to exclude regions of the movie, enter the number of regions, else 
type 0: '); 
    catch ME 
        disp(ME.message) 
    end 
end 
  
im1 = im(:,:,1); 
im1bp = imbp(:,:,1); 
  
xVert = cell(1,nRgn2Exclude); 
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yVert = cell(1,nRgn2Exclude); 
  
if nRgn2Exclude>0 
    ROImask = zeros(h,w,nRgn2Exclude); 
    for m=1:nRgn2Exclude; 
        close all 
        figure('name',[filename ': frame 1']) 
        imagesc(im1) 
        colormap('gray') 
        title('Choose one region to exclude') 
        hold on 
        for r = 1:m-1 
            plot(xVert{r},yVert{r},'r') 
        end 
        display('Use the polygon tool to create an ROI which you do not want tracked, then double click in 
that region.') 
        [ROImask(:,:,m),xVert{m},yVert{m}] = roipoly; 
    end 
    % put all ROI masks into 1 matrix; don't double count overlapping masks 
    rgns2remove = sum(ROImask,3)>0; 
else 




invertedMask = 1-rgns2remove ; %inverted mask - these are the pixels to keep 
im1bp = im1bp.*invertedMask; 
 
 
Function for discriminating true particles from noise 
 
function  [pos,eccen_cut] = particleDiscrimination_dissertation(num_images,cntAll,im,filename,lobject) 
  
% This function is used to discriminate true particles from noise based on 
% the particle size, brigthtness (mass), and eccentricity.  
% 




colors = jet(num_images); 
  
scrnsize = get(0,'ScreenSize'); 
  
happy = 0; 
while happy == 0 
     
    disp([num2str(size(cntAll,1)) ' spots identified']) 
     
    %plot radius vs brightness 
    f1 = figure(1); 
    set(f1,'Position',[100 (scrnsize(4)-600) 675 500]) 
    hold on 
    for i = 1:num_images, 
        rows = find(cntAll(:,6) == i); 
        plot(cntAll(rows,3),cntAll(rows,4),'.','color',colors(i,:),'MarkerSize',6) 
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    end 
    title('Select true particles') 
    xlabel('brightness') 
    ylabel('radius of gyration squared') 
     
    % choose points in (brigthness,radius) plane by drawing a polygon 
    % around them. 
    disp('Draw a polygon on Figure 1 around the points you would like to keep.') 
    h = impoly; 
    poly_vert = getPosition(h); 
     
    % determine which points are within the polygon 
    rows2keep = inpolygon(cntAll(:,3),cntAll(:,4),poly_vert(:,1),poly_vert(:,2)); 
    % only keep those particles 
    cntAllKeep = cntAll(rows2keep,:); 
     
    disp([num2str(size(cntAllKeep,1)) ' spots kept']) 
     
    % show the particles identified in the last image 
    f2 = figure(2); 
    set(f2,'Position',[100 (scrnsize(4)-600) 675 500]) 
    imagesc(im),colormap('gray') 
    hold on 
    lastcnt = cntAllKeep((cntAllKeep(:,6)==num_images),:); 
     
    theta = linspace(0,2*pi,50); %thanks to Kilfoil lab's code for this     
    for c = 1:size(lastcnt,1) 
        cx = lastcnt(c,1) + lobject/2*cos(theta); 
        cy = lastcnt(c,2) + lobject/2*sin(theta); 
        plot(cx,cy,'r-','linewidth',1) 
    end     
    title('Particles identified in last frame of movie') 
    axis square 
     
    %plot particle eccentricity vs brightness 
    f3 = figure(3); 
    set(f3,'Position',[800 (scrnsize(4)-600) 675 500]) 
    hold on 
    for i = 1:num_images, 
        rows = find(cntAllKeep(:,6) == i); 
        plot(cntAllKeep(rows,3),cntAllKeep(rows,5),'.','color',colors(i,:)) 
    end 
    title('Use eccentricity to exclude noise') 
    xlabel('brightness') 
    ylabel('eccentricity') 
    disp('Draw a polygon on Figure 3 around the points you would like to keep.') 
         
    h=impoly; 
    poly_vert = getPosition(h); 
    rows2keep = inpolygon(cntAllKeep(:,3),cntAllKeep(:,5),poly_vert(:,1),poly_vert(:,2)); 
    eccen_cut = NaN;     
     
    cntAllKeep = cntAllKeep(rows2keep,:); 
    disp([num2str(size(cntAllKeep,1)) ' spots kept']) 
     
    % show the particles identified in the last image 
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    f4 = figure(4); 
    set(f4,'Position',[800 (scrnsize(4)-600) 675 500]) 
    imagesc(im),colormap('gray') 
    hold on 
    lastcnt = cntAllKeep((cntAllKeep(:,6)==num_images),:); 
    for c = 1:size(lastcnt,1) 
        cx = lastcnt(c,1) + lobject/2*cos(theta); 
        cy = lastcnt(c,2) + lobject/2*sin(theta); 
        plot(cx,cy,'g-','linewidth',1) 
    end     
    title('Particles identified in last frame of movie') 
    axis square 
    title('Particles identified in last frame of movie') 
         
    happy = input('Satisfied with particle discrimination? 1 for yes, 0 for no: '); 
    while ~(happy == 0 || happy == 1) 
        happy = input('Improper entry. Satisfied with particle discrimination? 1 for yes, 0 for no: '); 
    end 
     
    if happy == 0 
        close all 
    else 
        print(f1,[filename(1:end-4) ' - particle detection.jpg'],'-djpeg') 
        print(f3,[filename(1:end-4) ' - particle detection2.jpg'],'-djpeg') 






Function for discriminating true particles from noise for a batch of movies 
 
function  [pos,brightness_cut,eccen_cut] = ... 
    batchParticleDiscrimination_dissertation(num_images,cntAll,im,filename,lobject) 
  
% This function is used to discriminate true particles from noise based on 
% the particle size, brigthtness (mass), and eccentricity. 
% 




colors = jet(num_images); 
  
scrnsize = get(0,'ScreenSize'); 
  
happy = 0; 
while happy == 0 
     
    disp([num2str(size(cntAll,1)) ' spots identified']) 
     
    %plot radius vs brightness 
    f1 = figure(1); 
    set(f1,'Position',[100 (scrnsize(4)-600) 675 500]) 
    hold on 
    for i = 1:num_images, 
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        rows = find(cntAll(:,6) == i); 
        plot(cntAll(rows,3),cntAll(rows,4),'.','color',colors(i,:),'MarkerSize',6) 
    end 
    title('Select true particles') 
    xlabel('brightness') 
    ylabel('radius of gyration squared') 
     
    brightness_cut = input('Enter brightness cutoff. Particles with brightness < cutoff will be discarded: '); 
    rows2keep = cntAll(:,3) >= brightness_cut; 
    cntAllKeep = cntAll(rows2keep,:); 
     
    disp([num2str(size(cntAllKeep,1)) ' spots kept']) 
     
    % show the particles identified in the last image 
    f2 = figure(2); 
    set(f2,'Position',[100 (scrnsize(4)-600) 675 500]) 
    imagesc(im),colormap('gray') 
    hold on 
    lastcnt = cntAllKeep((cntAllKeep(:,6)==num_images),:); 
     
    %  plot(lastcnt(:,1),lastcnt(:,2),'ro','MarkerSize',6); %faster 
    theta = linspace(0,2*pi,50); %thanks to Kilfoil lab's code for this     
    for c = 1:size(lastcnt,1) 
        cx = lastcnt(c,1) + lobject/2*cos(theta); 
        cy = lastcnt(c,2) + lobject/2*sin(theta); 
        plot(cx,cy,'r-','linewidth',1) 
    end     
    title('Particles identified in last frame of movie') 
    axis square 
     
    %plot particle eccentricity vs brightness 
    f3 = figure(3); 
    set(f3,'Position',[800 (scrnsize(4)-600) 675 500]) 
    hold on 
    for i = 1:num_images, 
        rows = find(cntAllKeep(:,6) == i); 
        plot(cntAllKeep(rows,3),cntAllKeep(rows,5),'.','color',colors(i,:)) 
    end 
    title('Use eccentricity to exclude noise') 
    xlabel('brightness') 
    ylabel('eccentricity') 
     
    eccen_cut = input('Enter eccentricity cutoff. Particles with value larger than cutoff will be discarded: '); 
    if ~(eccen_cut > 0 && eccen_cut <= 1) 
        eccen_cut = 0.3; 
        disp('Improper entry. Default to eccentricity cutoff of 0.3'); 
    end 
    rows2keep = cntAllKeep(:,5) <= eccen_cut; 
    cntAllKeep = cntAllKeep(rows2keep,:); 
    disp([num2str(size(cntAllKeep,1)) ' spots kept']) 
     
    % show the particles identified in the last image 
    f4 = figure(4); 
    set(f4,'Position',[800 (scrnsize(4)-600) 675 500]) 
    imagesc(im),colormap('gray') 
    hold on 
120 
 
    lastcnt = cntAllKeep((cntAllKeep(:,6)==num_images),:); 
    for c = 1:size(lastcnt,1) 
        cx = lastcnt(c,1) + lobject/2*cos(theta); 
        cy = lastcnt(c,2) + lobject/2*sin(theta); 
        plot(cx,cy,'g-','linewidth',1) 
    end 
    title('Particles identified in last frame of movie') 
    axis square 
    title('Particles identified in last frame of movie') 
         
    happy = input('Satisfied with particle discrimination? 1 for yes, 0 for no: '); 
    while ~(happy == 0 || happy == 1) 
        happy = input('Improper entry. 1 for yes, 0 for no: '); 
    end 
     
    if happy == 0 
        close all 
    else 
        print(f1,[filename(1:end-4) ' - particle detection.jpg'],'-djpeg') 
        print(f3,[filename(1:end-4) ' - particle detection2.jpg'],'-djpeg') 
  





Function for selecting a threshold to separate foreground and background 
 
function threshold = simplethresh_dissertation(filename,nRgn2Exclude,xVert,yVert,im1,im1bp) 
  
% Method for discriminating particles from background noise, using simple 
% thresholding. 
% 
% Benjamin Schuster, JHU, 2012-2014 
  
scrnsize = get(0,'ScreenSize'); 
figpos1 = [50 550 1500 425]; 
figpos2 = [50 50 1500 425]; 
if (figpos1(1)+figpos1(3))>scrnsize(3) || (figpos1(2)+figpos1(4))>scrnsize(4) 
    figpos1 = [0 0 .75*scrnsize(3) .4*scrnsize(4)]; 
    figpos2 = [0 0 .75*scrnsize(3) .4*scrnsize(4)]; 
end 
opengl('software') %helps with the graphical output; otherwise axis labels appear upside-down 
  
%Plot 1, different views to help see appropriate threshold 
figure('name',[filename ': Choose tracking threshold based on bandpassed images']) 
set(gcf,'Position', figpos1) 
ax1 = axes('position',[.04 .1 .2 .8],'units','normalized'); 
ax2 = axes('position',[.28 .1 .2 .8],'units','normalized'); 
ax3 = axes('position',[.52 .1 .2 .8],'units','normalized'); 
ax4 = axes('position',[.76 .1 .2 .8],'units','normalized'); 
%subplot 1 
imagesc(im1,'Parent',ax1),%colormap(ax1,'gray') 
title(['frame 1 raw, overlayed with ' num2str(nRgn2Exclude) ' regions to exclude'],'Parent',ax1) 
hold(ax1,'on') 
for r = 1:nRgn2Exclude 
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title(['frame 1 bandpassed, ' num2str(nRgn2Exclude) ' regions excluded'],'Parent',ax2) 
hold(ax2,'on') 
for r = 1:nRgn2Exclude 
    plot(xVert{r},yVert{r},'color','r','Parent',ax2) 
end 
%subplot 3 
mesh(im1bp,'Parent',ax3),%colormap(ax3,'jet') %then all 3 become jet ??? 
set(ax3,'YDir','reverse','View',[0 65]) 




title('frame 1 surface plot, view 2','Parent',ax4) 
  
%Plot 2, shows default threshold, found by Otsu's method 
figure('name',[filename ': Default threshold']) 
set(gcf,'Position', figpos2) 
ax1 = axes('position',[.05 .1 .27 .8],'units','normalized'); 
ax2 = axes('position',[.37 .1 .27 .8],'units','normalized'); 
ax3 = axes('position',[.69 .1 .27 .8],'units','normalized'); 
%subplot 1 
imagesc(im1,'Parent',ax1),%colormap(ax1,'gray') 
title(['frame 1 raw, overlayed with ' num2str(nRgn2Exclude) ' regions to exclude'],'Parent',ax1) 
hold(ax1,'on') 
for r = 1:nRgn2Exclude 






bb = mat2gray(im1bp); 
levelbb = graythresh(bb); % MATLAB's image threshold using Otsu's method 
level = levelbb*(max(im1bp(:)) - min(im1bp(:))) + min(im1bp(:)); 
set(ax2,'Zlim',[0 level]); 
title('frame 1 surface plot, zoom','Parent',ax2) 
%subplot 3 





disp(['default threshold: ' num2str(level)]) 
  
% Give user option to accept calculated threshold, or manually choose 
% threshold instead 
userinput = input('Enter 1 to keep default, 0 to input manual threshold: '); 
while ~(userinput == 0 || userinput == 1) 
    userinput = input('Improper entry. Enter 1 to manually input threshold, 0 to keep default: '); 
end 
accept = 0; 
while accept == 0 
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    if userinput == 0 
        threshold = input('Enter threshhold: '); 
        figure 
        imagesc(im1bp>threshold) 
        title('Thresholded image') 
        colormap('gray') 
        accept = input('Enter 1 to accept manual threshold, 0 to change it: '); 
    elseif userinput == 1 
        threshold = level; 
        accept = 1; 






Function for bandpass filtering an image 
 
function imbp = bpass_dissertation(im,lnoise,lobject) 
% 
% Bandpas filter 
% 
% Filters the input image using a real-space bandpass filter. Reduces pixel 
% noise and long-wavelenth image variations, while retaining features of 
% the desired size. 
% 
% inputs: im: Original image (must be floating-point data type), with bright 
%             spots against a dark background. 
%         lnoise: Lengthscale of noise in pixels, usually set as 1. Can set 
%                 to 0 to omit Gaussian smoothing. 
%         lobject: Length in pixels, slightly larger than size of particle 
%                  image; must be odd. 
% output: imbp: Bandpass filtered image 
% 
% This code is based upon Blair and Dufresne's bpass.m in MATLAB, which was 
% adapted from Crocker and Grier's bpass.pro in IDL. 
% 
% Modified by Benjamin Schuster, JHU, 2012-2014. 
% 
% Helpful explanation from the original authors: 
% "Performs a bandpass by convolving with an appropriate kernel.  You can 
% think of this as a two part process.  First, a lowpassed image is 
% produced by convolving the original with a Gaussian.  Next, a second 
% lowpassed image is produced by convolving the original with a boxcar 
% function. By subtracting the boxcar version from the Gaussian version, we 
% are using the boxcar version to perform a highpass. Performing a lowpass  
% and a highpass results in a bandpassed image." 
  
if mod(lobject,2) == 0 
    disp('lobject must be odd'); 
    return; 
end 
  
w = (lobject-1)/2; 





if lnoise == 0 
    gk = 0; 
else 
    normalize = @(x) x/sum(x); 
    gaussian_kernel = normalize(exp(-(x/(2*lnoise)).^2)); 
    gk = gaussian_kernel'*gaussian_kernel; 
end 
% If lobject is 9 or more, you capture almost 100% of the Gaussian. 
% If lobject is small, you start truncating the Gaussian kernel. 
% It should be OK down to lobject = 7 . 
  
%boxcar kernel 
bk = ones(lobject,lobject)/lobject^2; %boxcar kernel 
  
%Convolve the image with the kernel. (We can apply the Gaussian and boxcar 
%kernels in one step because of the distributive property of convolutions.) 
imbp = conv2(im,gk-bk,'same'); 
  
% Zero out the values at the edges of the image, since they're not useful. 
imbp(1:w,:) = 0; 
imbp((end - w + 1):end,:) = 0; 
imbp(:,1:w) = 0; 
imbp(:,(end - w + 1):end) = 0; 
  
% Zero out negative pixels, since negative pixels shift the centroid peak. 
imbp(imbp < 0) = 0; 
 
 




% Peak finder 
% 
% Finds local maxima in an image with pixel resolution. This provides a 
% first approximation of particle locations, which will subsequently be 
% refined. The code does this by by performing grayscale dilation on the 
% image and then finding the union of the dilated image with the original 
% image. Note, this only keeps one (the brightest) maxima within the radius 
% of the structuring element used to do the image dilation. Only local  
% maxima above a specified brigthness threshold are retained.  
% Secondarily, this function also calculates the background 
% noise in the image, which is used to estimate the signal-to-noise ratio. 
% 
% inputs: im: Original image (must be floating-point data type) 
%         imbp: Bandpass-filtered image 
%         th: Threshold value - minimum brightness of a local maximum pixel 
%             from a true particle; dimmer particles are just noise and 
%             will be discarded 
%         SE: Structuring element for imdilate 
% output: pk: An array containing coordinates of the identified local 
%             maxima (peaks). pk(:,1) stores the x coordinates and 
%             pk(:,2) the y coordinates of the local maxima. 
%         noisemean: Average pixel value of the background in image im. 




% The peak finding algorithm is based on Crocker and Grier (1996). The 
% noise calculation is based on Savin and Doyle (2005).  
% 
% Benjamin Schuster, JHU, 2012-2014. 
% 
% Note: imdilate() uses the MATLAB Image Processing Toolbox. Alternative 
% approaches are available to find the local maxima without using 
% imdilate(). 
  
% Conversion from floating point to uint16 makes imdilate() 2x faster, and  
% shouldn't hurt the results. But for this to work right, we need to scale 
% imbp to use the full range of values available; otherwise, we will lose 
% pixel-to-pixel differences due rounding, especially for images with 
% low contrast. 
maximbp = max(imbp(:)); 
imbpsc = uint16((2^16-1)*imbp/maximbp); %scale to use full 16-bit range of uint16 
imdil = imdilate(imbpsc,SE); %grayscale image dilation with structuring element SE 
pk = []; 
% Local maxima are the union of the image and its dilation. Only keep local 
% maxima above the previously determined brightness threshold. 
[pk(:,2), pk(:,1)] = find(imdil == imbpsc & imdil > (2^16-1)*th/maximbp); 
% pk(:,1) stores the x coordinates (im columns), pk(:,2) the y coordinates  
% (im rows) of the local maxima 
  
%%% Slower method 
% imdil = imdilate(imbp,SE); 
% pk = []; 
% [pk(:,2),pk(:,1)]=find(imdil == imbp & imdil>th); 
  
%%% To plot the identified particle locations on top of the image: 
% figure, imagesc(im), hold on, plot(pk(:,1),pk(:,2),'k.') 
%%% And to plot the identified local maxima on the dilated image: 
% figure, imagesc(imdil), hold on, plot(pk(:,1),pk(:,2),'k.') 
  
% The following code is used for calculating the background noise, which we 
% will use to estimate the signal-to-noise ratio. 
% Only keep the dimmer 50% of pixels for making the noise mask. Other   
% cutoff values could be used, such as mean or a different percentile.  
NoiseMask = imdil < median(imdil(:)); 
NoiseRegW0 = NoiseMask.*im; % regions we'll use to calculate noise are nonzero 
NoisePix = nonzeros(NoiseRegW0); % discard zeros; calculate noise from remaining pixels  
noisestd = std(NoisePix); 
noisemean = mean(NoisePix); 
 
 
Function for calculating intensity-weighted centroids (centers) of particles 
 
function cntrds = cntrd_dissertation(im,pk,sz,interactive) 
% 
% This function calculates centroids of candidate particles. It takes the 
% local maxima pixels identified previously and computes refined estimates  
% of the particle centers. This permits sub-pixel resolution if the 
% images are of sufficient quality. 
% 
% inputs: im: Original image (must be floating-point data type) 
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%         pk: Array of local maxima (peaks) in the image, output from pkfnd 
%         sz: Diameter of ROI over which to calculate the centroid. Should 
%             be large enough to capture the whole particle of interest, 
%             but not others. 
%         interactive: Optional plot, only displays if "interactive" is set 
%             to 1. Displays the location of the brightest pixel and the  
%             centroid on the ROI 
% 
% output:  cntrds, a n_pks x 5 array containing the centroid 
%          locations and particle measurements 
%           cntrds(:,1) contains the x-coordinates 
%           cntrds(:,2) contains the y-coordinates 
%           cntrds(:,3) contains the particles' brightness 
%           cntrds(:,4) contains the square of the radius of gyration 
%           cntrds(:,5) contains the eccentricity 
% 
% This code is based upon Blair and Dufresne's cntrd.m in MATLAB, which was 
% adapted from Crocker and Grier's IDL code. Eccentricity calculation 
% is based on MATLAB code from the Kilfoil lab. Note, this function does 
% not contain all the features of Crocker and Grier's IDL centroid code. 
% 
% Modified by Benjamin Schuster, JHU, 2012-2014. 
  
if nargin==3 
    interactive=0; 
end 
  
if mod(sz,2) == 0 
    disp('sz must be odd'); 




    disp('No positions were input into cntrd. Check your pkfnd threshold.') 
    cntrds=[]; 
    return; 
end 
  
mdpt = (sz+1)/2; 
w = (sz-1)/2; 
r = sz/2; 
  
% create mask - window around candidate particle location over which to  
% calculate the centroid 
c_array = meshgrid(1:sz,1:sz)-mdpt; %same values within a column 
r_array = c_array'; %same values within a row 
dst2 = r_array.^2+c_array.^2; 
msk = double(dst2 <= r^2); % Crocker and Grier paper uses <= w^2  
  
% masks for eccentricity calculation, adapted from Maria Kilfoil's code 
thetas = atan2(r_array,c_array); 
cmsk = cos(2*thetas).*msk; 
smsk = sin(2*thetas).*msk; 
  
n_pks = size(pk,1); 




if interactive == 1 
    figure 
end 
  
%loop through all of the candidate positions     
maxiters = 5; 
for i=1:n_pks 
    %select neighborhood around each candidate location, and apply the mask 
    roi = msk.*im((pk(i,2)-w:pk(i,2)+w),(pk(i,1)-w:pk(i,1)+w)); 
    %calculate the total brightness 
    tot_brightness = sum(roi(:)); 
    %calculate the weighted average x location 
    xavg = sum(sum(roi.*c_array))/tot_brightness; 
    %calculate the weighted average y location 
    yavg = sum(sum(roi.*r_array))/tot_brightness; 
  
    % If the calculated centroid is more than half a pixel in either 
    % direction from the center of the brightest pixel, recalculate the 
    % centroid using the previous estimate. Repeat if necessary, but not 
    % for more than maxiters iterations. 
    iters = 0; 
    while (abs(xavg) > 0.5 || abs(yavg) > 0.5) && iters < maxiters 
        iters = iters + 1; 
         
        if abs(xavg) > 0.5 
            pk(i,1) = pk(i,1) + round(xavg); 
        end 
         
        if abs(yavg) > 0.5 
            pk(i,2) = pk(i,2) + round(yavg); 
        end 
         
        roi = msk.*im((pk(i,2)-w:pk(i,2)+w),(pk(i,1)-w:pk(i,1)+w)); 
        tot_brightness = sum(roi(:)); 
        xavg = sum(sum(roi.*c_array))/tot_brightness; 
        yavg = sum(sum(roi.*r_array))/tot_brightness; 
    end 
  
    %store the refined centroid locations and particle brighness data 
    cntrds(i,1) = pk(i,1) + xavg; 
    cntrds(i,2) = pk(i,2) + yavg; 
    cntrds(i,3) = tot_brightness; 
     
    %calculate the radius of gyration^2 
    cntrds(i,4) = sum(sum(roi.*dst2))/tot_brightness; 
     
    %calculate the eccentricity 
    numer1 = sum(sum(roi.*cmsk)); 
    numer2 = sum(sum(roi.*smsk)); 
    denom = tot_brightness - roi(mdpt,mdpt); 
    cntrds(i,5) = sqrt(numer1^2 + numer2^2)/denom; %eccentricity     
     
    % Optional plot, only displays if "interactive" is set to 1. Displays 
    % the location of the brightest pixel and the centroid on the ROI. 
    if interactive==1 
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        imagesc(roi) 
        colormap('jet') 
        axis image 
        hold on 
        plot(mdpt+xavg,mdpt+yavg,'mx') 
        plot(mdpt+xavg,mdpt+yavg,'mo') 
        plot(mdpt,mdpt,'k.') 
        title(['brightness ',num2str(tot_brightness),', size ', ... 
            num2str(sqrt(cntrds(i,4))), ' eccentricity ', ... 
            num2str(cntrds(i,5))]) 
        pause 




Function for linking particle locations into trajectories 
 
function B = mytracker_dissertation(pos,maxdisp,memory_nframes,min_frames) 
  




% pos: the first dimn columns are the dimn particle cordinates; the last 
%      (dimn+1) column is frame # 
% maxdisp: maximum displacement a particle could go from one frame to next 
% memory_nframes: is # of consecutive frames a particle can go out of view 
%  and be tracked as the same particle; 0 if no memory 
% min_frames: eliminate trajectories with fewer than this number of frames 
% 
% output: 
% list of trajectories 
% 
% Benjamin Schuster, JHU, 2012-2014 
  
dimn = 2; %dimensionality of the particle coordinate data 
maxdispSq = maxdisp^2; 
  
[r,c] = size(pos); 
PosConn = zeros(r,c+1); %the added column is for storing the trajectory # 
PosConn(:,1:dimn+4) = pos; 
  
% check the input time vector 
t = pos(:,dimn+4); 
dt = t(2:end) - t(1:end-1); %indicates where the frame number changes 
if dt == 0 
    disp('Error - All positions are at the same time') 
    return 
elseif sum(dt<0) ~= 0 
    disp('Error - The time vector is not in order') 
    return 
elseif sum(dt>1) ~= 0 
    disp('Error - Some frames have no particles detected') 





indices = [find(dt > 0); length(t)]; %index of last row of pos data for every frame 
num_frames = length(indices); 
indices = [0; indices]; 
  
%lost_p{i} is list of particles whose last known location occurs in frame i, 
%then particle is missing from frame i + 1 
lost_p = cell(num_frames-1,1); 
for i = 1:num_frames-1 
    M = indices(i+1)-indices(i); 
    %Initialize lost_p{i} to list all the particles in frame i; later we'll 
    %remove those that have been assigned to a trajectory. 
    lost_p{i} = (1:M)'; 
end 
  
PosConn(1:indices(2),end) = 1:indices(2); %all the particles in first frame are assinged new trajectory ID # 
pcount = indices(2); %number of trajectories so far 
disp('Starting tracking routine'); 
for i = 2:num_frames %loop over the frames 
    if i == 2 
        mxmem = 0; 
    elseif i < memory_nframes + 2 %memory (# of skipped frames) must be adjusted for the first few frames 
        mxmem = i - 2; 
    else 
        mxmem = memory_nframes; 
    end 
     
    N = indices(i+1)-indices(i); %# of particles detected in frame i 
    indices_current = (indices(i)+1):indices(i+1); 
    pos_current = PosConn(indices_current,1:dimn); 
     
    not_assigned_n = 1:N; %list of particles in frame i not yet assigned to a particle in frame i-1 
    colID = 1:N; 
     
    for h = 0:mxmem %look to frames i-1 through i-1-mxmem to "connect the dots" in frame i 
        if ~isempty(not_assigned_n) && ~isempty(lost_p{i-1-h}) 
             
            M = indices(i-h)-indices(i-1-h); %# of spots detected in frame i-1-h 
            indices_prev = (indices(i-1-h)+1):indices(i-h); 
            pos_prev = PosConn(indices_prev,:); 
             
            %             %%% This is slow when there are a lot of particles!! 
            %             %matrix of all possible "bond lengths" squared 
            %             DeltaSq = NaN*ones(M,N); %NaN remains for particles that have already been assigned 
            %             for m = lost_p{i-1-h}'  %m down the rows 
            %                 for n = not_assigned_n %n across the columns 
            %                     DeltaSq(m,n) = sum((pos_current(n,1:dimn) - pos_prev(m,1:dimn)).^2); 
            %                 end 
            %             end 
             
            % This is faster. But note we're still doing lots of extra 
            % computations (calculating "bond lengths" that are much 
            % larger than maxdispSq, such as from particles on opposite 
            % sides of the image field). 
            pos_current2 = NaN(size(pos_current)); 
            pos_current2(not_assigned_n,:) = pos_current(not_assigned_n,:); 
            pos_prev2 = NaN(size(pos_prev)); 
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            pos_prev2(lost_p{i-1-h},:) = pos_prev(lost_p{i-1-h},:); 
             
            DeltaX = zeros(M,N,dimn); 
            for dd = 1:dimn %loop over the x, y (and z if applicable) coordinates 
                for n = 1:N %n across the columns 
                    DeltaX(:,n,dd) = pos_current2(n,dd) - pos_prev2(:,dd); 
                end 
            end 
            DeltaSq = sum(DeltaX.^2,3); 
             
            %bonds shorter than the user-specified maximum 
            EligibleBonds = DeltaSq < maxdispSq; 
            row_sum = sum(EligibleBonds); 
            col_sum = sum(EligibleBonds,2); 
             
            rowID = (1:M)'; 
            for n = not_assigned_n %loop over not yet assigned particles in frame i 
                %note: not_assigned_n changes within this loop. MATLAB 
                %still loops over all elements that are in not_assigned_n when 
                %the loop begins. 
                 
                %conn_m gives spots in frame i-1 that spot n in frame i could be connected to 
                conn_m = rowID(EligibleBonds(:,n)); %uses logical indexing 
                 
                % if row_sum(n) == 0 %no eligible bonds - don't do anything 
                if row_sum(n) == 1 && col_sum(conn_m) == 1 %trivial bond case 
                    %give spot n the trajectory ID of spot m 
                    PosConn(indices(i)+n,end)= pos_prev(conn_m,end); 
                    %remove n from list of not assigned particles in frame i 
                    not_assigned_n(not_assigned_n == n) = []; 
                    %remove m from list of not assigned particles in frame i-1-h 
                    lost_p{i-1-h}(lost_p{i-1-h} == conn_m) = []; 
                elseif row_sum(n) > 0 %non-trivial bonds 
                    %Identify the subnetwork 
                    subnetwork = cell(1,2); 
                    new_ms = conn_m; 
                    new_ns = n; 
                    while ~isempty(new_ns) %new_ms will be empty if new_ms is 
                        subnetwork{1} = [subnetwork{1}; new_ms]; %spots from frame i-1 in subnetwork 
                        subnetwork{2} = [subnetwork{2}, new_ns]; %spots from frame i in subnetwork 
                         
                        EligibleBonds(:,new_ns) = 0; %to prevent working on the same particle twice 
                        row_sum(new_ns) = -1; %to prevent working on the same particle twice 
                        new_ns = []; 
                        for k = 1:length(new_ms) 
                            new_ns = [new_ns, colID(EligibleBonds(new_ms(k),:))]; 
                        end 
                        new_ns = unique(new_ns); 
                         
                        EligibleBonds(new_ms,:) = 0; %to prevent working on the same particle twice 
                        %col_sum(new_ms) = -1; %not necessary 
                        new_ms = []; 
                        for k = 1:length(new_ns) 
                            new_ms = [new_ms; rowID(EligibleBonds(:,new_ns(k)))]; 
                        end 
                        new_ms = unique(new_ms); 
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                    end 
                     
                    %Warning about combinatorics if subnetwork is large 
                    len_sntwk_m = length(subnetwork{1}); 
                    len_sntwk_n = length(subnetwork{2}); 
                    if len_sntwk_m > 10 || len_sntwk_n > 10 
                        disp('Excessive combinatorics. Exiting now.') 
                        disp('Check parameters (especially max displacement).') 
                        return 
                    elseif len_sntwk_m > 7 || len_sntwk_n > 7 
                        disp('Difficult combinatorics.') 
                    end 
                     
                    %Determine the optimal set of bonds for the subnetwork 
                    if len_sntwk_m <= len_sntwk_n 
                        %list of possible perutations of the n's in subnetwork 
                        P = perms(subnetwork{2}); 
                        %account for unequal # of spots in subnetwork in the 2 frames 
                        P2 = unique(P(:,1:len_sntwk_m),'rows'); 
                        BondLenSq = zeros(size(P2)); 
                        for j = 1:size(P2,1) 
                            idx = sub2ind([M N],subnetwork{1}', P2(j,:)); 
                            bondlensq_1perm = DeltaSq(idx); 
                            if bondlensq_1perm<maxdispSq 
                                BondLenSq(j,:) = bondlensq_1perm; 
                            else 
                                % rule out permutations with any bond length >= max displacement 
                                BondLenSq(j,:) = NaN; 
                                % better to use penalty than NaN? 
                            end 
                        end 
                        sumbonds = sum(BondLenSq,2); 
                        [minsum,best_perm_id] = min(sumbonds); 
                        bestn = P2(best_perm_id,:); 
                        bestm = subnetwork{1}; 
                    else %len_sntwk_m > len_sntwk_n 
                        P = perms(subnetwork{1}); 
                        P2 = unique(P(:,1:len_sntwk_n),'rows'); 
                        BondLenSq = zeros(size(P2)); 
                        for j = 1:size(P2,1) 
                            idx = sub2ind([M N],P2(j,:),subnetwork{2}); 
                            bondlensq_1perm = DeltaSq(idx); 
                            if bondlensq_1perm<maxdispSq 
                                BondLenSq(j,:) = bondlensq_1perm; 
                            else 
                                BondLenSq(j,:) = NaN; 
                            end 
                        end 
                        sumbonds = sum(BondLenSq,2); 
                        [minsum,best_perm_id] = min(sumbonds); 
                        bestm = P2(best_perm_id,:); 
                        bestn = subnetwork{2}; 
                    end 
                    PosConn(indices(i)+bestn,end)= pos_prev(bestm,end); 
                     
                    % keep record of which particles have been assigned 
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                    for j = 1:length(bestn) %note bestm and bestn will have equal lengths 
                        not_assigned_n(not_assigned_n == bestn(j)) = []; 
                        lost_p{i-1-h}(lost_p{i-1-h} == bestm(j)) = []; 
                    end 
                     
                end 
            end %end of loop over n 
             
        end 
    end %end of loop over previous frames (memory) 
     
    %particles that are still unassigned become start of new trajectories 
    for k = 1:length(not_assigned_n) 
        pcount = pcount + 1; 
        PosConn(indices(i)+not_assigned_n(k),end) = pcount; 
    end 
     
    %update user on tracking progress 
    if mod(i,25)==0 
        disp(['tracking - finished ' num2str(i) ' frames']) 
    end 
     
end 
  
S = sortrows(PosConn,size(PosConn,2)); %sort by trajectory number 
S2 = [S(:,dimn+5) S(:,dimn+4) S(:,1:dimn+3)]; %reorder the columns 
% now the columns are (left to right): particle number, frame number, spatial 
% coordinates, particle brightness, radius of gyration, and eccentricity 
num_particles = S2(end,1); 
  
%find # of frames for each particle 
frames = zeros(1,num_particles); 
for i=1:num_particles 
    frames(i)=sum(S2(:,1)==i); 
end 
  
% %remove particles (trajectories) with fewer than min_frames 
% much slower! 
% tic 
% for k=num_particles:-1:1 
%     if frames(k)<min_frames 
%         rows=sum(frames(1:k)); 
%         S2=[S2(1:(rows-frames(k)),:);S2((rows+1):end,:)]; 





particles2keep = find(frames >= min_frames); 
S2 = S2(ismember(S2(:,1),particles2keep),:); 
  
%re-number the particles 
j=1; 
S3 = S2; 
S3(1,1) = 1; 




    dt = S2(i,2)-S2(i-1,2); 
    if S2(i,1)~=S2(i-1,1); 
        j=j+1; 
    elseif dt ~= 1 
        gaps = [gaps; (i-1) dt]; %record index and length of gaps/skipped frames 
    end 
    S3(i,1)=j; 
end 
num_particles=j; % # of particles 
  
Bcell = cell(2*size(gaps,1)+1,1); 
gaps(end+1,:) = [size(S3,1) NaN]; 
Bcell{1} = S3(1:gaps(1,1),:); 
for k=1:size(gaps,1)-1 
    Binsertion = []; 
    %     v = zeros(1,dimn+2); 
    v = NaN*ones(1,dimn+5); % for skipped frames, set the position coordinates to NaN 
    v(1) = 0; 
    v(2) = 1; 
    for j = 1:gaps(k,2)-1 
        Binsertion = [Binsertion; S3(gaps(k,1),:) + v]; 
        v(2) = v(2) + 1; 
    end 
    Bcell{2*k} = Binsertion; 
    Bcell{2*k+1} = S3(gaps(k,1)+1:gaps(k+1,1),:); 
end 





Function for formatting the trajectory data 
 
function [B,Timescale,particles,frames] = process_MPT_data_dissertation(B,frame_rate) 
  
% Formats the raw MPT data file 
% 
% Benjamin Schuster, JHU, 2012-2014 
  
max_frame=max(B(:,2)); %determine largest # of frames from column 2 of the input file 
  
%create timescale vector 
Timescale=(1:max_frame-1)/frame_rate; 
  
%Rewrite 1st column of matrix so paricles are numbered sequentially, 
%starting from 1. Necessary to calculate MSD from multiple movies in a group.  
j=0; 
for i=1:length(B); 
    if B(i,2)==1; 
        j=j+1; 
    end 
    B(i,1)=j; 
end 




%find # of frames for each particle 
frames = zeros(1,particles); 
for i=1:particles 




Function for calculating the mean squared displacement (MSD) 
 
function [MSD,MSDx,MSDy,d_shortest_t,num_displacements] = ... 
    calculate_MSD_dissertation(B,Timescale,particles,frames,conv) 
  
% Input: Particle trajectories (tracked in 2 dimensions) 
% Output: Retuns an array whose columns are each particle's MSD 
% 






num_displacements = zeros(length(Timescale),particles); 
  
d_shortest_t = []; 
  
for j=1:particles %loop over particles 
    %create a temporary matrix containing 1 particle worth of data 
    C=B((1:frames(j))+sum(frames(1:j-1)),:); 
     
    %calculate MSD for each time scale 
    for k=1:frames(j)-1; 
        xdisps = C(1+k:end,3)-C(1:end-k,3); 
        xdisps = xdisps(~isnan(xdisps)); 
        count = length(xdisps); 
        ydisps = C(1+k:end,4)-C(1:end-k,4); 
        ydisps = ydisps(~isnan(ydisps)); 
        if k == 1 
             d_shortest_t = [d_shortest_t; sqrt(xdisps.^2 + ydisps.^2)]; 
        end 
        num_displacements(k,j) = count; 
        MSDx(k,j) = conv^2*sum((xdisps).^2)/count; %if no NaNs, count =(frames(j)-k); %um^2 
        MSDy(k,j) = conv^2*sum((ydisps).^2)/count; %um^2 
        MSD(k,j) = MSDx(k,j)+MSDy(k,j); %um^2 




Function for creating particle tracking movie with trajectories overlaid 
 
function makeTrajectoryMovie_dissertation(filename,ext,movieprofile,fpers,... 
    movie_display,movieInfo,X,Y,xVert,yVert,nRgn2Exclude,startf,stopf) 
  
% After tracking is completed, make movie with trajectories overlayed. 
% 




% Note: There is a problem with how MATLAB saves the output movies, which 
% makes it appear that the trajectories are displaced one pixel down and 
% right compared to where they should be - i.e. the identified particle 
% centroid appears to be one pixel off in x and y from the brightest 
% pixel in the particle. This is not a problem with the centroid 
% calculation, nor is this problem present in the output movie displayed 
% when the code is running - it is just an issue with how the movie is saved 
% using getframe() and writevideo(). 
  
if movie_display == 1 
    disp('Starting video writing. Do not resize or move figure window while movie is being written!') 
else 
    disp('Starting video writing.'); 
end 
  
movieobj = VideoWriter([filename(1:(end-length(ext))) ' - tracked movie'],movieprofile); 
movieobj.FrameRate = fpers; 
open(movieobj); 
  
m = movieInfo(1).Height; 
n = movieInfo(1).Width; 
  
f = figure('Units','pixels','Position',[150 150 n m],'visible','off','renderer','zbuffer'); 
ax1 = axes('Parent',f,'Position',[0 0 1 1],'units','normalized'); 
set(ax1,'XLim',[0 n],'YLim',[0 m],'YDir','reverse','visible','off'); 
if strcmp(ext,'.mov') 
    movieobjin = VideoReader(filename); 
end 
  
for i = startf:stopf %only make a movie of the frames that were tracked 
    cla(ax1) 
     
    if strcmp(ext,'.tif') 
        im = double(imread(filename, i, 'Info', movieInfo)); %Info speeds imread for multi-image tiff 
    elseif strcmp(ext,'.mov') 
        moviecdata = read(movieobjin,i); 
        im = 256*3 - sum(moviecdata,3); 
    end 
     
    imagesc('Parent',ax1,'CData',im,'AlphaData',1) 
    colormap(ax1,'gray') 
    hold(ax1,'on') 
    for r = 1:nRgn2Exclude 
        plot(xVert{r},yVert{r},'color','r','Parent',ax1) 
    end 
     
    shiftedi=i-startf+1; 
     
    RestX = X(shiftedi:end,:); 
    FinishedTracksID = all(isnan(RestX),1); 
     
    NotFinishedTracksX = [X(1:shiftedi,~FinishedTracksID); NaN(1,sum(~FinishedTracksID))]; 
    NotFinishedTracksY = [Y(1:shiftedi,~FinishedTracksID); NaN(1,sum(~FinishedTracksID))]; 
    FinishedTracksX = [X(1:shiftedi,FinishedTracksID); NaN(1,sum(FinishedTracksID))]; 
    FinishedTracksY = [Y(1:shiftedi,FinishedTracksID); NaN(1,sum(FinishedTracksID))]; 
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    % since vectors are faster to plot than arrays 
    NotFinishedTracksX2 = reshape(NotFinishedTracksX,numel(NotFinishedTracksX),1); 
    NotFinishedTracksY2 = reshape(NotFinishedTracksY,numel(NotFinishedTracksY),1); 
    FinishedTracksX2 = reshape(FinishedTracksX,numel(FinishedTracksX),1); 
    FinishedTracksY2 = reshape(FinishedTracksY,numel(FinishedTracksY),1); 
     
    line(NotFinishedTracksX2,NotFinishedTracksY2,'color','b'); % line() is faster than plot() 
    line(FinishedTracksX2,FinishedTracksY2,'color','w'); 
     
    if movie_display == 1 
        frm = getframe(f); 
    else %if movie_display == 0 
        frm = im2frame(zbuffer_cdata(gcf)); 
    end 
     
    writeVideo(movieobj,frm); 
    if mod(i,25)==0 
        disp(['video writing - frame ' num2str(i) ' done']) 
    end 
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